Compounds for treatment of coronavirus infections

Abstract

The present invention generally relates to SARS-CoV-2 related 3C-like protease (Mpro) inhibitors useful in the treatment of coronavirus infections, characterized by comprising the following formula (A). The present invention also provides a method of inhibiting coronavirus replication comprising administering to a subject a compound of formula (A) or a pharmaceutical composition comprising the compound. # imgabs0 #

Description

Cross-references to related applications

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 353,354, filed June 17, 2022, entitled “Compounds for treatment of a coronavirus infection”, and U.S. Provisional Patent Application Serial No. 63 / 414,287, filed October 7, 2022, entitled “Compounds for treatment of a coronavirus infection”, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Technical Field

[0002] This invention relates to inhibitors of coronavirus replication activity. The inhibitors described herein can be used to treat diseases caused by coronavirus infection, including COVID-19 caused by SARS-CoV-2 infection. Specifically, this invention relates to compounds and pharmaceutical compositions that inhibit SARS-CoV-2-related 3C-like proteases, methods for treating coronavirus infections, and methods for synthesizing these compounds. Background Technology

[0003] Coronaviruses are a large family of viruses that typically cause mild to moderate upper respiratory tract illness in humans. However, three coronaviruses have caused more severe and deadly illness in humans: SARS coronavirus (SARS-CoV), which emerged in November 2002 and caused severe acute respiratory syndrome (SARS); MERS coronavirus (MERS-CoV), which emerged in 2012 and caused Middle East respiratory syndrome (MERS); and SARS-CoV-2, which emerged in 2019 and caused coronavirus disease 2019 (COVID-19).

[0004] Infection with severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 causes coronavirus disease 2019 (COVID-19).

[0005] The virus that causes COVID-19 spreads easily from person to person. Data shows that COVID-19 primarily spreads between close contacts (within approximately 6 feet or 2 meters). COVID-19 can also spread from infected individuals who are asymptomatic. This is known as asymptomatic transmission. COVID-19 can also spread from infected individuals who are not yet showing symptoms. This is known as presymptomatic transmission. It is possible to contract COVID-19 after reinfection with SARS-CoV-2, and this can happen more than once.

[0006] Whole-genome sequencing revealed that SARS-CoV-2 shares 79.6% sequence identity with SARS-CoV. SARS-CoV-2 appears to have a relatively high transmissibility rate in humans and causes severe and fatal pneumonia and other damage, threatening people of all ages, particularly the elderly and those with pre-existing conditions including immunodeficiency, lung disease, metabolic disorders, and other illnesses. With the rapid increase in infections and deaths, there is an urgent need to develop drugs to combat COVID-19.

[0007] SARS-CoV-2 is a complex virus composed of three open reading frames expressing a multiprotein. The multiprotein undergoes proteolytic processing to become its mature, active form. Although the spike glycoprotein is cleaved by cathepsin L and TMPRSS2, the remaining proteolytic steps are mediated by one of two virus-encoded proteases: the main protease (Mpro or 3C-like protease (3CLpro)) and the papain-like protease PLpro. Mpro plays a crucial role in the maturation of viral proteins required for RNA replication and is a preferred target for developing direct-acting antiviral drugs capable of inhibiting SARS-CoV-2 infection. The SARS-CoV-2 Mpro enzyme shares approximately 96% similarity with SARS-CoV.

[0008] Given the ongoing spread of SARS-CoV-2 that is causing the current worldwide COVID-19 outbreak, it is desirable to have new methods to suppress SARS-CoV-2 viral replication and treat COVID-19 patients. Summary of the Invention

[0009] The first aspect of the present invention relates to compounds comprising formula (A): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; R M Selected from M is selected from 5-10 membered heterocyclic groups or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 1 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 2 Together, they form an oxygen metabolism; Or R 2 and R 3 Together they form a double bond; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; R 4 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; n is an integer selected from 0, 1, and 2; m is an integer selected from 0 and 1; The condition is when R q When it is H, then R 1 and R 4Together with the atoms it is attached to and any intermediate atoms, it forms 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocyclic or 5-6 membered heteroaryl; in, Cycloalkyl groups are monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms; Aryl groups are cyclic aromatic hydrocarbon groups having one to three aromatic rings; Heterocyclic groups are saturated or partially unsaturated 3-10 member monocyclic, 7-12 member bicyclic (fused ring, bridged ring or spirocyclic) or 11-14 member tricyclic (fused ring, bridged ring or spirocyclic) ring systems having one or more heteroatoms selected from O, N, S, P, Se or B. A heteroaryl group is a monovalent monocyclic or polycyclic aromatic group having 5 to 24 ring atoms, wherein the monovalent monocyclic or polycyclic aromatic group contains one or more cyclic heteroatoms selected from N, O, S, P or B, and the remaining ring atoms are C.

[0010] On the other hand, the present invention relates to compounds comprising formula (I): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; R 1 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 2 Together, they form an oxygen metabolism; Or R 2 and R 3 Together they form a double bond; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; R 4 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; n is an integer selected from 0, 1, and 2; The condition is when R q When it is H, then R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocyclic or 5-6 membered heteroaryl; in, Cycloalkyl groups are monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms; Aryl groups are cyclic aromatic hydrocarbon groups having one to three aromatic rings; Heterocyclic groups are saturated or partially unsaturated 3-10 member monocyclic, 7-12 member bicyclic (fused ring, bridged ring or spirocyclic) or 11-14 member tricyclic (fused ring, bridged ring or spirocyclic) ring systems having one or more heteroatoms selected from O, N, S, P, Se or B. A heteroaryl group is a monovalent monocyclic or polycyclic aromatic group having 5 to 24 ring atoms, wherein the monovalent monocyclic or polycyclic aromatic group contains one or more cyclic heteroatoms selected from N, O, S, P or B, and the remaining ring atoms are C.

[0011] On the other hand, the present invention relates to compounds comprising formula (II): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; M is selected from 5-10 membered heterocyclic groups or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 1 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 2 Together, they form an oxygen metabolism; Or R 2 and R 3 Together they form a double bond; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; R 4Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; m is an integer selected from 0 and 1; n is an integer selected from 0, 1, and 2; The condition is when Rq When it is H, then R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocyclic or 5-6 membered heteroaryl; in, Cycloalkyl groups are monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms; Aryl groups are cyclic aromatic hydrocarbon groups having one to three aromatic rings; Heterocyclic groups are saturated or partially unsaturated 3-10 member monocyclic, 7-12 member bicyclic (fused ring, bridged ring or spirocyclic) or 11-14 member tricyclic (fused ring, bridged ring or spirocyclic) ring systems having one or more heteroatoms selected from O, N, S, P, Se or B. A heteroaryl group is a monovalent monocyclic or polycyclic aromatic group having 5 to 24 ring atoms, wherein the monovalent monocyclic or polycyclic aromatic group contains one or more cyclic heteroatoms selected from N, O, S, P or B, and the remaining ring atoms are C.

[0012] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0013] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0014] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0015] Another aspect of the invention relates to a method for treating coronavirus infection (such as COVID-19). The method comprises administering to a patient requiring treatment for a coronavirus infection (such as COVID-19) an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0016] Another aspect of the invention relates to a method for treating coronavirus infection (such as COVID-19). The method comprises administering to a patient requiring treatment for a coronavirus infection (such as COVID-19) an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0017] Another aspect of the invention relates to a method for treating coronavirus infection (such as COVID-19). The method comprises administering to a patient requiring treatment for a coronavirus infection (such as COVID-19) an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0018] Another aspect of the invention relates to a method for inhibiting or preventing the replication of the SARS-CoV-2 virus. The method involves administering to a patient in need an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0019] Another aspect of the invention relates to a method for inhibiting or preventing the replication of the SARS-CoV-2 virus. The method involves administering to a patient in need an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0020] Another aspect of the invention relates to a method for inhibiting or preventing the replication of the SARS-CoV-2 virus. The method involves administering to a patient in need an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0021] Another aspect of the present invention relates to compounds of formula (A) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of medicaments for inhibiting or preventing the replication of SARS-CoV-2 virus.

[0022] Another aspect of the present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of drugs for inhibiting or preventing the replication of SARS-CoV-2 virus.

[0023] Another aspect of the present invention relates to compounds of formula (II) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of medicaments for inhibiting or preventing the replication of SARS-CoV-2 virus.

[0024] Another aspect of the present invention relates to the use of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of diseases or conditions associated with SARS-CoV-2 virus infection.

[0025] Another aspect of the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of diseases or conditions associated with SARS-CoV-2 virus infection.

[0026] Another aspect of the invention relates to the use of compounds of formula (II) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof in the treatment of diseases or conditions associated with SARS-CoV-2 virus infection.

[0027] Another aspect of the present invention relates to compounds of formula (A) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of medicaments for the treatment or prevention of viral infections disclosed herein.

[0028] Another aspect of the present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of medicaments for the treatment or prevention of viral infections disclosed herein.

[0029] Another aspect of the present invention relates to compounds of formula (II) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the preparation of medicaments for the treatment or prevention of viral infections disclosed herein.

[0030] Another aspect of the invention relates to a method for treating or preventing coronavirus infection (such as COVID-19) in a subject in need. The method involves administering an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof to a patient in need of treatment.

[0031] Another aspect of the invention relates to a method for treating or preventing coronavirus infection (such as COVID-19) in a subject in need. The method involves administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof to a patient in need of treatment.

[0032] Another aspect of the invention relates to a method for treating or preventing coronavirus infection (such as COVID-19) in a subject in need. The method involves administering an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof to a patient in need of treatment.

[0033] Another aspect of the invention relates to the use of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of coronavirus infection.

[0034] Another aspect of the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of coronavirus infection.

[0035] Another aspect of the invention relates to the use of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of coronavirus infection.

[0036] The present invention further provides a method for treating coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0037] The present invention further provides a method for treating coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0038] The present invention further provides a method for treating coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof.

[0039] This invention provides a viral replication activity inhibitor, which is a therapeutic agent for treating coronavirus infection.

[0040] This invention provides a SARS-CoV-2-associated 3C-like protease inhibitor, which is a therapeutic agent for treating coronavirus infection.

[0041] This invention provides a SARS-CoV-2-associated Mpro protease inhibitor, which is a therapeutic agent for treating coronavirus infection.

[0042] The present invention further provides compounds and compositions that have improved efficacy and safety compared to known SARS-CoV-2-associated 3C-like protease inhibitors.

[0043] The present invention further provides a method for treating a disease or condition associated with coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0044] The present invention further provides a method for treating a disease or condition associated with coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0045] The present invention further provides a method for treating a disease or condition associated with coronavirus infection, the method comprising administering to a patient suffering from coronavirus infection a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0046] This invention provides a SARS-CoV-2-associated 3C-like protease inhibitor, which is a therapeutic agent for treating coronavirus infection.

[0047] This invention provides a SARS-CoV-2-associated Mpro protease inhibitor, which is a therapeutic agent for treating coronavirus infection.

[0048] This invention further provides compounds and compositions with improved efficacy and safety compared to known SARS-CoV-2-associated 3C-like protease inhibitors. This invention further provides agents with novel mechanisms of action against SARS-CoV-2-associated 3C-like proteases in the treatment of coronavirus infections.

[0049] This invention further provides compounds and compositions with improved efficacy and safety compared to known SARS-CoV-2-associated Mpro protease inhibitors. This invention also provides agents with novel mechanisms of action against SARS-CoV-2-associated Mpro protease in the treatment of coronavirus infections.

[0050] The present invention further provides methods for preventing, treating or improving coronavirus infection.

[0051] The present invention further provides a method for treating diseases, conditions, or symptoms selected from: the common cold; pneumonia (direct viral pneumonia or secondary bacterial pneumonia); bronchitis (direct viral bronchitis or secondary bacterial bronchitis); severe acute respiratory syndrome (SARS); Middle East respiratory syndrome (MERS); coronavirus disease 2019 (COVID-19); coronavirus HuPn-2018, the method comprising administering to a patient suffering from at least one of the diseases or conditions a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0052] The present invention further provides a method for treating diseases, conditions, or symptoms selected from: the common cold; pneumonia (direct viral pneumonia or secondary bacterial pneumonia); bronchitis (direct viral bronchitis or secondary bacterial bronchitis); severe acute respiratory syndrome (SARS); Middle East respiratory syndrome (MERS); coronavirus disease 2019 (COVID-19); coronavirus HuPn-2018, the method comprising administering to a patient suffering from at least one of the diseases or conditions a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0053] The present invention further provides a method for treating diseases, conditions, or symptoms selected from: the common cold; pneumonia (direct viral pneumonia or secondary bacterial pneumonia); bronchitis (direct viral bronchitis or secondary bacterial bronchitis); severe acute respiratory syndrome (SARS); Middle East respiratory syndrome (MERS); coronavirus disease 2019 (COVID-19); coronavirus HuPn-2018, the method comprising administering to a patient suffering from at least one of the diseases or conditions a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0054] In some aspects, the present invention provides a compound that can be obtained by or through a method for preparing the compound described herein (e.g., a method comprising one or more steps described in a general procedure).

[0055] In some aspects, the present invention provides an intermediate as described herein, which is suitable for methods of preparing compounds as described herein (e.g., the intermediate is selected from the intermediates described in the preparation section - preparation 1-278).

[0056] In some aspects, the present invention provides a method for preparing the compounds of the present invention.

[0057] In some aspects, the present invention provides a method for preparing the compounds of the present invention, the method comprising one or more steps described in the present invention.

[0058] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In this specification, the singular form includes the plural form unless the context clearly requires otherwise. Although methods and materials similar to or equivalent to those described in this invention may be used in the practice or testing of this invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned in this invention are incorporated herein by reference. References cited in this invention are not considered prior art to the claimed invention. In case of conflict, this specification (including definitions) shall prevail. Furthermore, materials, methods, and examples are illustrative only and are not intended to be restrictive. In case of conflict between the chemical structure and name of the compounds disclosed in this invention, the chemical structure shall prevail.

[0059] Other features and advantages of the invention will become apparent from the following detailed description and claims. Implementation

[0060] This invention provides a method for treating, preventing, or improving coronavirus-related viral infections by administering a therapeutically effective amount of a compound as disclosed herein to a subject in need.

[0061] Details of the invention are set forth in the following description. Although similar or equivalent methods and materials may be used in the practice or testing of the invention, illustrative methods and materials are described hereafter. Other features, objects, and advantages of the invention will become apparent from the description and claims. In this specification and the appended claims, the singular form includes the plural form unless the context clearly requires otherwise. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. All patents and disclosures referenced in this specification are incorporated herein by reference in their entirety. definition

[0062] The articles “a” and “an” are used in this invention to refer to one or more (i.e., at least one) grammatical objects of the articles. For example, “element” means one or more elements.

[0063] Unless otherwise stated, the term "and / or" is used in this invention to mean "and" or "or".

[0064] The term "optionally substituted" is understood to mean that a given chemical moiety (e.g., alkyl) may (but is not required to) be bonded to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group may be a fully saturated alkyl chain (i.e., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group may have one or more substituents other than hydrogen. For example, the same optionally substituted alkyl group may be bonded to a halogen atom, a hydroxyl group, or any other substituent described in this invention at any point along the chain. Thus, the term "optionally substituted" means that a given chemical moiety may contain other functional groups, but does not necessarily have any additional functional groups. The substituents used in the optional substitutions applicable to the described groups include, but are not limited to, halogens, oxo groups, -OH, -CN, -NH2, -NO2, -COOH, -CH2CN, -O-(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)ynyl, (C2-C6)alkenyl, (C2-C6)ynyl, -O P(O)(OH)2, -OC(O)(C1-C6)alkyl-C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -NHC(O)(C1-C6)alkyl, -C(O)NH(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and -S(O)N((C1-C6)alkyl)2. The substituents themselves may optionally be substituted. As used herein, "optionally substituted" also refers to substituted or unsubstituted, as described below.

[0065] As used herein, the term "substituted" means that a specified group or portion has one or more suitable substituents, wherein the substituents may be attached to the specified group or portion at one or more positions. For example, an aryl group substituted with a cycloalkyl group may indicate that the cycloalkyl group is attached to one atom of the aryl group by a bond or by fusion with the aryl group and sharing two or more common atoms.

[0066] As used in this invention, the term "unsubstituted" means that the specified group does not contain substituents.

[0067] Unless otherwise specifically defined, the term "aryl" refers to a cyclic aromatic hydrocarbon group having one to three aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. In the case of two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl) or fused (e.g., naphthyl). The aryl group may optionally be substituted with one or more substituents (e.g., one to five substituents) at any connection point. Exemplary substituents include, but are not limited to, -H, -halogen, -O-(C1-C6)alkyl, (C1-C6)alkyl, -O-(C2-C6)alkenyl, -O-(C2-C6)ynyl, (C2-C6)alkenyl, (C2-C6)ynyl, -OH, -OP(O)(OH)2, -OC(O)(C1-C6)alkyl, -C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -S(O)2-(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and -S(O)N((C1-C6)alkyl)2. The substituent itself may optionally be substituted. Furthermore, when containing two fused rings, the aryl group as defined in this invention may have one or more saturated or partially unsaturated rings fused to a fully unsaturated aromatic ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracene, benzonaphthyl, phenanthryl, indanyl, indenyl, tetrahydronaphthyl, tetrahydrobenzoanthyl, etc.

[0068] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic or polycyclic aromatic group containing 5 to 24 ring atoms selected from N, O, S, P, or B, with the remaining ring atoms being C. Polycyclic aromatic groups include two or more fused rings and may further include two or more spirofused rings, such as bicyclic, tricyclic, tetracyclic, etc. Unless otherwise specifically defined, "fused" means two rings sharing two ring atoms. Unless otherwise specifically defined, "spirofused" means two rings sharing one ring atom. As defined in this invention, "heteroaryl" also means a bicyclic heteroaromatic group, wherein the heteroatom is selected from N, O, S, P, or B. As defined in this invention, "heteroaryl" also means a tricyclic aromatic group containing one or more ring atoms selected from N, O, S, P, or B. As defined in this invention, "heteroaryl" also means a tricyclic heteroaromatic group containing one or more ring atoms selected from N, O, S, P, or B. The aromatic groups may optionally be independently substituted by one or more substituents as described in this invention.Examples include, but are not limited to, furanyl, thiophene, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazoleyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indoleyl, thiophene-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazolyl, indazoleyl, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furan[2,3-c]pyridyl, imidazo[1,2-a]pyridyl, indazoleyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrazolo[3,4-c]pyridyl, thieno[3,2-c]pyridyl, thiophene [2,3-c]pyridyl, thieno[2,3-b]pyridyl, benzothiazolyl, indolinyl, indolinonyl, dihydrobenzothiophene, dihydrobenzofuran, benzofuran, benzodihydropyranyl, thiobenzodihydropyranyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthidyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthidyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazo[1,5-a]pyridyl, [1,2,4]triazo[4,3-a]pyridyl, iso Indole, pyrrolo[2,3-b]pyridyl, pyrrolo[3,4-b]pyridyl, pyrrolo[3,2-b]pyridyl, imidazo[5,4-b]pyridyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1-pyrrolo[2,1-b]pyrimidinyl, dibenzo[b,d]thiophene, pyridin-2-one, furano[3,2-c]pyridyl, furano[2,3-c]pyridyl, 1H-pyridano[3,4-b][1,4]thiazinyl, benzoxazoleyl, benzoisoxazoleyl, furano[2,3-b]pyridyl, benzothiopheneyl, 1,5-naphthidylyl Furano[3,2-b]pyridyl, [1,2,4]triazolo[1,5-a]pyridyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridyl, thiazo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadi. Azolyl, thieno[2,3-b]pyrrole, 3H-indolyl, and their derivatives. Furthermore, when containing two or more fused rings, the heteroaryl group as defined in this invention may have one or more saturated or partially unsaturated rings fused to one or more fully unsaturated aromatic rings. In heteroaryl ring systems containing more than two fused rings, the saturated or partially unsaturated rings may be further fused to the saturated or partially unsaturated rings described in this invention. Furthermore, when containing three or more fused rings, the heteroaryl group as defined in this invention may have one or more saturated or partially unsaturated spirofused rings. Any saturated or partially unsaturated ring described in this invention may optionally be substituted with one or more oxygen groups. Exemplary ring systems of these heteroaryl groups include, for example, indololinyl, indololinone, dihydrobenzothiophene, dihydrobenzofuran, benzodihydropyranyl, thiobenzodihydropyranyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranone, hydroxyindolyl, indolyl, 1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolazinyl, 8H-pyrido[3,2-b]pyrrolazinyl, 1,5,6,7-tetrahydrocyclopentan[b]pyrazolo[4,3-e]pyrrolazinyl The following are listed: pyridyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizine, pyrazolo[1,5-a]pyrimidin-7(4H)-keto, 3,4-dihydropyrazolo[1,2-a]indole-1(2H)-keto, benzo[c][1,2]oxaborpentane-1(3H)-azole, 6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-keto, or 6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrido[1,2-d][1,4]oxazin]-9'-keto.

[0069] "Halogen" or "halogenated" refers to fluorine, chlorine, bromine, or iodine.

[0070] Alkyl refers to a straight-chain or branched saturated hydrocarbon containing 1 to 12 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0071] "Alkoxy" refers to a straight-chain or branched saturated hydrocarbon containing 1-12 carbon atoms, with a terminal "O", i.e., -O (alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, or pentoxy.

[0072] "Alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2-12 carbon atoms. An alkenyl group contains at least one double bond in its chain. The double bond in an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include vinyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl. Alkenyl groups can be unsubstituted or substituted. As defined in this invention, alkenyl groups can be straight-chain or branched.

[0073] "Alynyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2 to 12 carbon atoms. An alkynyl group contains at least one triple bond in its chain. Examples of alynyl groups include ethynyl, propynyl, n-butynyl, isobutynyl, pentyynyl, or hexynyl. Alynyl groups can be unsubstituted or substituted.

[0074] The term "alkylene" or "alkylenyl" refers to a divalent alkyl group. Any of the monovalent alkyl groups mentioned above can be an alkylene group by removing the second hydrogen atom from an alkyl group. As defined in this invention, alkylene groups can also be C1-C6 alkylene groups. Alkylene groups can further be C1-C4 alkylene groups. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc.

[0075] “Cycloalkyl” means a monocyclic or polycyclic saturated carbon ring containing 3 to 18 carbon atoms. A polycyclic cycloalkyl group can be a fused bicyclic cycloalkyl group, a bridged bicyclic cycloalkyl group, or a spirofused bicyclic cycloalkyl group. A polycyclic cycloalkyl group contains at least one non-aromatic ring. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, 1,2,3,4-tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, spiro[3.5]nonyl, spiro[5.5]undecyl, bicyclic[1.1.1]pentyl, bicyclic[2.2.2]octyl, or bicyclic[2.2.2]octenyl.

[0076] Heterocyclic groups, "heterocyclic" or "heterocyclic alkyl" monocyclic or polycyclic compounds containing 3-24 atoms, said atoms comprising carbon and one or more heteroatoms selected from N, O, S, P or B, and said ring is not aromatic. Heterocyclic alkyl ring structures may be substituted with one or more substituents. The substituents themselves may optionally be substituted. Examples of heterocyclic rings include, but are not limited to, oxacyclobutane, azacyclobutane, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolinyl, thiazolinyl, thiazolinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxazolynyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazine, azaphenyl, oxazolinyl, diazaphenyl, tropanyl, oxazolidinone, and homotropanyl.

[0077] The term "aromatic" refers to a planar ring having 4n+2 electrons in a coupled system. As used in this invention, "coupled system" refers to a system with connected p orbitals containing delocalized electrons, and said system may include lone pairs.

[0078] As used in this invention, the term "haloalkyl" refers to an alkyl group as defined herein, wherein the alkyl group is substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.

[0079] As used in this invention, the term "haloalkoxy" refers to an alkoxy group as defined in this invention, wherein the alkoxy group is substituted with one or more halogens. Examples of halogenated alkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

[0080] As used in this invention, the term "cyano" refers to a substituent having a carbon atom connected to a nitrogen atom via a triple bond, i.e., C≡N.

[0081] "Spirocycloalkyl" or "spirocycloyl" refers to a carbon-source bicyclic ring system in which two rings are linked by a single atom. The rings can be of different sizes and properties or the same size and properties. Examples include spiropentane, spirohexane, spiroheptane, spiroctane, spirononane, or spirodecane. One or both rings in a spirocyclic ring can be fused with another ring of carbon, a heterocyclic ring, an aromatic ring, or a heteroaromatic ring. One or more carbon atoms in a spirocyclic ring can be substituted with heteroatoms (e.g., O, N, S, or P). (C3-C) 12 Spirocycloalkyl is a spirocyclic ring containing between 3 and 12 carbon atoms. One or more of the carbon atoms may be replaced by heteroatoms.

[0082] The terms “spiroheteroalkyl”, “spiroheterocyclic”, or “spiroheterocyclic group” should be understood to mean a spirocyclic ring in which at least one ring is a heterocyclic ring (e.g., at least one ring is furanyl, morpholinyl, or piperidinyl).

[0083] The term "solvent" refers to a complex formed by a solute and a solvent with a variable stoichiometry. Such solvents used for the purposes of this invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates of water molecules are generally referred to as hydrates. Hydrates include compositions containing a stoichiometric amount of water, as well as compositions containing a variable amount of water.

[0084] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and / or chemical properties. Structural differences can lie in composition (geometric isomers) or the ability to rotate the plane of polarized light (stereoisomers). Regarding stereoisomers, compounds of formula (A) may have one or more asymmetric carbon atoms and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereomers.

[0085] The present invention also considers isotopically labeled compounds of formula (A) (e.g., using...). 2 H and 14 Those marked with C). Tritium (i.e., 2 H or D) and carbon-14 (i.e., ... 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Additionally, substitution with a heavier isotope (such as deuterium) can provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirement), and may therefore be preferred in some cases. Isotopically labeled compounds of formula (I) can generally be prepared by substituting a non-isotopically labeled reagent with a suitable isotopically labeled reagent via a procedure similar to those disclosed in the schemes and / or examples below.

[0086] The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of the disclosed compound and a pharmaceutically acceptable carrier. Representative “pharmaceutically acceptable salts” include, for example, water-soluble and water-insoluble salts such as acetates, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonates, benzoates, bicarbonates, bisulfates, tartrates, borates, bromides, butyrates, calcium, calcium edetate, camphorsulfonates, carbonates, chlorides, citrates, clavulariate, dihydrochlorides, ethylenediaminetetraacetate, ethanedisulfonate, propionate, dodecyl sulfate, ethanesulfonate, fumarate, gluconate, gluconate, glutamate, glycolyl-p-aminobenzoarsine, hexafluorophosphate, hexylresorcinol, hydrazine. (bamine), hydrobromide, hydrochloride, hydroxynaphthylcarboxylate, iodide, isothiosulfate, lactate, lacturonate, laurate, magnesium, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucilage, naphthalene sulfonate, nitrate, N-methylglucosamine ammonium salt, 3-hydroxy-2-naphthylcarboxylate, oleate, oxalate, palmitate, dihydroxynaphthylcarboxylate, pantothenate, phosphate / bisphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, basic acetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, theochloroate, toluenesulfonate, triethyliodide, and valerate.

[0087] "Patient" or "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0088] When used in conjunction with a compound, “effective amount” refers to an amount that is effective in treating or preventing a disease in a subject as described in this invention.

[0089] As used in this invention, the term "carrier" encompasses carriers, excipients, and diluents, and means materials, compositions, or media such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials that involve carrying or transporting a pharmaceutical agent from one organ or part of the body to another organ or part of the body of a subject.

[0090] The term "treatment" in relation to a subject refers to the improvement of at least one symptom of the subject's condition. Treatment includes curing, improving, or at least partially alleviating the condition.

[0091] Unless otherwise stated, the term "symptom" is used in this invention to mean the terms disease, symptom, or illness, and is used interchangeably with these terms.

[0092] As used herein, the terms “administer,” “administering,” or “administration” mean the direct administration of the disclosed compound or a pharmaceutically acceptable salt or composition of the disclosed compound to a subject, or the administration of a prodrug derivative or analog of the compound or a pharmaceutically acceptable salt or composition of the compound to a subject, which may form an equivalent amount of the active compound in the subject’s body.

[0093] As used in this invention, the term "prodrug" means a compound that can be converted into the disclosed compound in vivo via metabolism (e.g., by hydrolysis).

[0094] The term "salt" refers to a pharmaceutically acceptable salt.

[0095] The term "pharmaceutically acceptable salt" also refers to the salt of the composition of the present invention having an acidic functional group (such as a carboxylic acid functional group) and a base.

[0096] As used in this invention, "SARS-CoV-2-associated 3C-like protease inhibitor" refers to a compound of formula (A), (I), or (II) that inhibits SARS-CoV-2-associated 3C-like protease and / or a composition containing a compound of formula (A), (I), or (II).

[0097] As used in this invention, "SARS-CoV-2 virus replication inhibitor" refers to a compound of formula (A), formula (I) or formula (II) that inhibits the replication of SARS-CoV-2 virus and / or a composition containing a compound of formula (A), formula (I) or formula (II).

[0098] The term "SARS-CoV-2 inhibitor" means any SARS-CoV-2-related coronavirus 3C-like protease inhibitor compound described in this invention, or a pharmaceutically acceptable salt, hydrate, prodrug, active metabolite or solvate thereof, or a compound that inhibits SARS-CoV-2 replication in any way.

[0099] The amount of compounds in the compositions described in this invention required to achieve a therapeutic effect can be determined empirically based on conventional procedures for a particular purpose. Typically, for the administration of a therapeutic agent (e.g., the compounds or compositions of this invention described herein (and / or other pharmaceutical agents)) for a therapeutic purpose, the therapeutic agent is given at a pharmacologically effective dose.

[0100] "Pharmacologically effective amount," "pharmacologically effective dose," "therapeuticly effective amount," or "effective amount" means an amount sufficient to produce a desired physiological effect or to achieve a desired result, particularly an amount used to treat coronavirus infection. As used in this invention, an effective amount will include an amount sufficient to, for example, delay the development of symptoms of a condition or disease, alter the course of symptoms of a condition or disease (e.g., slow the progression of symptoms), alleviate or eliminate one or more symptoms or manifestations of a condition or disease, and reverse the symptoms of a condition or disease. Therapeutic benefits also include preventing or slowing the progression of an underlying disease or condition, whether or not improvement is achieved. The compounds of the present invention

[0101] On the one hand, the present invention provides compounds of formula (A) and their pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers: Where R N R q R M R 1 R 2 R 3 R 4 R 6 R 7 R 8 Q and X are as described in this invention.

[0102] It should be understood that for compounds of formula (A), R N R q R M R 1 R 2 R 3 R 4 R 6 R 7 R 8 Q and X can each be selected from the groups described in this invention where applicable, and this invention is directed toward R. N R q R M R 1 R 2 R 3 R 4 R 6 R 7 R 8 Any group described in any of Q and X may be used in conjunction with the present invention with respect to R, where applicable. N R q R M R 1 R 2 R 3R 4 R 6 R 7 R 8 Any combination of groups described by one or more of the remaining parts of Q and X.

[0103] On the other hand, the present invention provides compounds of formula (I) and their pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers: Where R N R q R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 Q and X are as described in this invention.

[0104] It should be understood that for compounds of formula (I), R N R q R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 Q and X can each be selected from the groups described in this invention where applicable, and this invention is directed toward R. N R q R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 Any group described in any of Q and X may be used in conjunction with the present invention with respect to R, where applicable. N R q R 1R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 Any combination of groups described by one or more of the remaining parts of Q and X.

[0105] On the other hand, the present invention provides compounds of formula (II) and their pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers: Where R N R q R 1 R 2 R 3 R 4 R 6 R 7 R 8 Q, M, m and X are as described in this invention.

[0106] It should be understood that for compounds of formula (I), R N R q R 1 R 2 R 3 R 4 R 6 R 7 R 8 Q, M, m, and X may each be selected from the groups described in this invention where applicable, and this invention is directed against R. N R q R 1 R 2 R 3 R 4 R 6 R 7 R 8 Any group described by any of Q, M, m, and X may be used in accordance with the present invention for R where applicable. N R q R 1 R 2 R 3 R 4 R 6 R 7 R 8Any combination of groups described by one or more of the remaining parts of Q, M, m and X.

[0107] In some embodiments, Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; R M Selected from M is selected from 5-10 membered heterocyclic groups or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 1 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 2 Together, they form an oxygen metabolism; Or R 2 and R 3 Together they form a double bond; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16replace; R 4 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Or R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms.13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; or Two Rs 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; n is an integer selected from 0, 1, and 2; m is an integer selected from 0 and 1.

[0108] In some embodiments, Q is selected from CR 5 R Q and NR Q .

[0109] In some embodiments, Q is CR 5 R Q .

[0110] In some embodiments, Q is NR Q .

[0111] In some embodiments, R Q It is R N .

[0112] In some embodiments, R Q It is H.

[0113] In some embodiments, R q It is H.

[0114] In some embodiments, R q and R Q They form bonds together.

[0115] In some embodiments, R q and R Q Together in C(R) q Another bond is formed between Q and Q.

[0116] In some embodiments, R q and R Q Together in C(R) q A second bond is formed between Q and Q.

[0117] In some embodiments, R N Selected from H, C1-C6 alkyl, and cycloalkyl.

[0118] In some embodiments, R N It is H.

[0119] In some embodiments, R N It is a C1-C6 alkyl group.

[0120] In some embodiments, R N It is CH3.

[0121] In some embodiments, R N It is a cycloalkyl group.

[0122] In some embodiments, R N It is cyclopropyl.

[0123] In some embodiments, R 1 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0124] In some embodiments, R 1 It is hydrogen.

[0125] In some embodiments, R 1 and R 2 Together they are oxygenated.

[0126] In some embodiments, R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0127] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 3-10 membered cycloalkyl groups.

[0128] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 6-membered cycloalkyl group.

[0129] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 3-10 membered cycloalkyl groups, and R 2 and R 3 Together they form a double bond.

[0130] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms 3-10 unsubstituted cycloalkyl groups, and R 2 and R 3 Together they form a double bond.

[0131] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 6-membered cycloalkyl group, and R 2 and R 3 Together they form a double bond.

[0132] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered unsubstituted cycloalkyl group, and R 2 and R 3 Together they form a double bond.

[0133] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered cycloalkyl group, R 2 and R 3 Together they form a double bond and the 6-membered cycloalkyl group is replaced by two C1-C6 alkyl groups.

[0134] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered cycloalkyl group, R 2 and R 3 Together they form a double bond and the 6-membered cycloalkyl group is replaced by two methyl groups.

[0135] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered cycloalkyl group, R 2 and R 3 Together they form a double bond and the 6-membered cycloalkyl group is replaced by two halogens.

[0136] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered cycloalkyl group, R 2 and R 3 Together they form a double bond and the 6-membered cycloalkyl group is replaced by two fluorine molecules.

[0137] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 The substituted 6-membered aryl group.

[0138] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered unsubstituted aryl group.

[0139] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group of atoms bound by an R. 16 The substituted 6-membered aryl group.

[0140] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a structure formed by two R atoms. 16 The substituted 6-membered aryl group.

[0141] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a structure consisting of three R atoms. 16 The substituted 6-membered aryl group.

[0142] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a structure consisting of four R atoms. 16 The substituted 6-membered aryl group.

[0143] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more halogens.

[0144] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more F atoms.

[0145] In some embodiments, R1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with an F.

[0146] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more Cl atoms.

[0147] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a Cl atom.

[0148] In some embodiments, R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 6-membered aryl group that optionally has one or more C1-C6 alkyl groups.

[0149] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more methyl groups.

[0150] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a methyl group.

[0151] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with two methyl groups.

[0152] In some embodiments, R 1 and R 4 Together with the atoms to which it is attached and any intermediate atoms, it forms a 6-membered aryl group that optionally has one or more C1-C6 alkoxy groups.

[0153] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more methoxy groups.

[0154] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a methoxy group.

[0155] In some embodiments, R 1and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Replaced 3-14 membered heterocycles.

[0156] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 The replaced 6-membered heterocycle.

[0157] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally containing nitrogen as a heteroatom and surrounded by one or more R atoms. 16 The replaced 6-membered heterocycle.

[0158] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally containing oxygen as a heteroatom and surrounded by one or more R atoms. 16 The replaced 6-membered heterocycle.

[0159] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group containing sulfur as a heteroatom, optionally bounded by one or more R atoms. 16 The replaced 6-membered heterocycle.

[0160] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 5-6 aryl groups.

[0161] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 Substituted 6-membered heteroaryl group.

[0162] In some embodiments, R 1 and R 4 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally containing nitrogen as a heteroatom and surrounded by one or more R atoms. 16 Substituted 6-membered heteroaryl group.

[0163] In some embodiments, R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0164] In some embodiments, R 2 It is H.

[0165] In some embodiments, R 2 and R 1 Together they are oxygenated.

[0166] In some embodiments, R 2 and R 3 Together they form a double bond.

[0167] In some embodiments, R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace.

[0168] In some embodiments, R 3 and R 2 Together they form a double bond.

[0169] In some embodiments, R 3 It is H.

[0170] In some embodiments, R 4 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 13 R 14 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0171] In some embodiments, R 4 It is H.

[0172] In some embodiments, R 4 It is -OH.

[0173] In some embodiments, R 4 It is halogen.

[0174] In some embodiments, R 4 It is F.

[0175] In some embodiments, R 4 It is a C1-C6 alkyl group.

[0176] In some embodiments, R 4 It is methyl. In some embodiments, R 4 It is ethyl. In some embodiments, R 4 It is propyl. In some embodiments, R 4 It is n-propyl. In some embodiments, R 4 It is isopropyl. In some embodiments, R 4 It is butyl. In some embodiments, R 4 It is n-butyl. In some embodiments, R 4 It is isobutyl. In some embodiments, R 4 It is n-butyl. In some embodiments, R 4 It is sec-butyl. In some embodiments, R 4 It is tert-butyl. In some embodiments, R 4 It is pentyl. In some embodiments, R 4 It is n-pentyl. In some embodiments, R 4 It is the foundation of righteousness.

[0177] In some embodiments, R 4 It is CH3.

[0178] In some embodiments, R 4 It is a C1-C6 alkoxy group.

[0179] In some embodiments, R 4 It is a methoxy group. In some embodiments, R 4 It is ethoxylated. In some embodiments, R 4 It is propoxy. In some embodiments, R 4 It is -OCH2CH2CH3. In some embodiments, R 4 It is -OCH(CH3)2. In some embodiments, R 4 It is a butoxy group. In some embodiments, R 4 It is -OCH2CH2CH2CH3. In some embodiments, R 4 It is -OCH2CH(CH3)2. In some embodiments, R 4 It is -OC(CH3)3. In some embodiments, R 4 It is an pentoxy group. In some embodiments, R 4 It is hexyloxy group.

[0180] In some embodiments, R 4 It is -OCH3.

[0181] In some embodiments, R 4 It is -OC2H5.

[0182] In some embodiments, R 4 It is -O-CH2CH2CH3.

[0183] In some embodiments, R 4 yes

[0184] In some embodiments, R 4 yes

[0185] In some embodiments, R 4 Yes -NR 6 R 7 .

[0186] In some embodiments, R 4 It is -NH2.

[0187] In some embodiments, R 4 It is -NHCH3.

[0188] In some embodiments, R 4 It is -N(CH3)2.

[0189] In some embodiments, R 4 yes

[0190] In some embodiments, R 4 yes

[0191] In some embodiments, R 4 yes

[0192] In some embodiments, R 4 yes

[0193] In some embodiments, R 4 It is -N(CH3)2.

[0194] In some embodiments, R 4 yes

[0195] In some embodiments, R 4 yes

[0196] In some embodiments, R 4 It is a heterocyclic group.

[0197] In some embodiments, R 4 yes

[0198] In some embodiments, R 4 yes

[0199] In some embodiments, R 4 It is controlled by a group R 5 Substituted C1-C6 alkoxy groups.

[0200] In some embodiments, R 4 It is a C1-C6 alkoxy group substituted with a cycloalkyl group.

[0201] In some embodiments, R 4 yes

[0202] In some embodiments, R 4 and R 1 Together with the atoms to which it is attached and any intermediate atoms, it forms a 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0203] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 16 The substituted 6-membered aryl group.

[0204] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered unsubstituted aryl group.

[0205] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more halogens.

[0206] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more F atoms.

[0207] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with an F.

[0208] In some embodiments, R 4 and R 1Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more Cl atoms.

[0209] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a Cl atom.

[0210] In some embodiments, R 4 and R 1 Together with the atoms to which it is attached and any intermediate atoms, it forms a 6-membered aryl group that optionally has one or more C1-C6 alkyl groups.

[0211] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more methyl groups.

[0212] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a methyl group.

[0213] In some embodiments, R 4 and R 1 Together with the atoms to which it is attached and any intermediate atoms, it forms a 6-membered aryl group that optionally has one or more C1-C6 alkoxy groups.

[0214] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with one or more methoxy groups.

[0215] In some embodiments, R 4 and R 1 Together with the atoms it is attached to and any intermediate atoms, it forms a 6-membered aryl group substituted with a methoxy group.

[0216] In some embodiments, R 5 Selected from hydrogen, deuterium, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 13 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups.16 replace.

[0217] In some embodiments, R 5 It is hydrogen.

[0218] In some embodiments, R 5 It is a C1-C6 alkyl group.

[0219] In some embodiments, R 6 Selected from H, C1-C6 alkyl, cycloalkyl, and -CH2-aryl.

[0220] In some embodiments, R 6 It is H.

[0221] In some embodiments, R 6 It is a C1-C6 alkyl group.

[0222] In some embodiments, R 6 It is a methyl group.

[0223] In some embodiments, R 6 It is an ethyl group.

[0224] In some embodiments, R 6 It is propyl.

[0225] In some embodiments, R 6 It's n-propyl.

[0226] In some embodiments, R 6 It is isopropyl.

[0227] In some embodiments, R 6 It is a cycloalkyl group.

[0228] In some embodiments, R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 13 R 14 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl.

[0229] In some embodiments, n is an integer selected from 0, 1, and 2.

[0230] In some embodiments, n is 2.

[0231] In some embodiments, n is 1.

[0232] In some embodiments, n is 0.

[0233] In some embodiments, R 7 It is -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 13 R 14 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl.

[0234] In some embodiments, R 7 It is -CH2-aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 13 R 14 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl.

[0235] In some embodiments, R 7 It is -CH2-phenyl.

[0236] In some embodiments, R 7 It is -CH2-aryl, wherein the aryl group is optionally substituted by one or more halogens.

[0237] In some embodiments, R 7 yes

[0238] In some embodiments, R 8 It is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl.

[0239] In some embodiments, R 8 It is hydrogen.

[0240] In some embodiments, R 8 It is a C1-C6 alkyl group.

[0241] In some embodiments, R 8 It is a methyl group.

[0242] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Replaced by 5-7 member monocyclic or bicyclic heterocyclic groups.

[0243] In some embodiments, R 7 and R 8Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 The substituted 5-membered monocyclic heterocyclic group.

[0244] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 The substituted 6-membered monocyclic heterocyclic group.

[0245] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 The substituted 7-membered monocyclic heterocyclic group.

[0246] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 The substituted 6-membered bicyclic heterocyclic group.

[0247] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 The substituted 7-membered bicyclic heterocyclic group.

[0248] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms

[0249] In some embodiments, R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms

[0250] In some embodiments, R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN.

[0251] In some embodiments, R 9 R 10 R 11 Each is a C1-C6 alkyl group.

[0252] In some embodiments, R 9 R 10 R 11 Each is a methyl group.

[0253] In some embodiments, R 9 R 10 R 11 Each is a halogen.

[0254] In some embodiments, R 9 R 10 R 11 Each is F.

[0255] In some embodiments, R 9 It is methyl, R 10 and R 11 Each is F.

[0256] In some embodiments, R 9 It is F, R 10 and R 11 Each is a methyl group.

[0257] In some embodiments, R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace.

[0258] In some embodiments, R 12 It is a C1-C6 alkyl-S(O)2-, wherein the alkyl group is optionally separated by one or more R 16 replace.

[0259] In some embodiments, R 12 It is CH3S(O)2-.

[0260] In some embodiments, R 12 It is CF3S(O)2-.

[0261] In some embodiments, R 12 It is CF3CH2S(O)2-.

[0262] In some embodiments, R 12 It is a cycloalkyl-S(O)2-, wherein the alkyl group is optionally separated by one or more R 16 replace.

[0263] In some embodiments, R 12 yes

[0264] In some embodiments, R 12 It is a C1-C6 alkyl-C(O)-, wherein the alkyl group is optionally separated by one or more R16 replace.

[0265] In some embodiments, R 12 It is CF3C(O)-.

[0266] In some embodiments, R 12 It is (CH3)2CHC(O)-.

[0267] In some embodiments, R 12 It is a C1-C6 alkyl-OC(O)-, wherein the alkyl group is optionally converted by one or more R 16 replace.

[0268] In some embodiments, R 12 It is (CH3)3C-OC(O)-.

[0269] In some embodiments, R 12 It is CH3OC(O)-.

[0270] In some embodiments, R 12 It is CH3CH2OC(O)-.

[0271] In some embodiments, R 12 It is (CH3)2CH-OC(O)-.

[0272] In some embodiments, R 12 It is a heteroaryl group.

[0273] In some embodiments, R 12 It is a 5-membered heteroaryl group.

[0274] In some embodiments, R 12 It is a 6-membered heteroaryl group.

[0275] In some embodiments, R 12 It is a 5-membered heteroaryl group containing one heteroatom.

[0276] In some embodiments, R 12 It is a 5-membered heteroaryl group containing 2 heteroatoms.

[0277] In some embodiments, R 12 It is a 5-membered heteroaryl group containing 3 heteroatoms.

[0278] In some embodiments, R 12 It is a 6-membered heteroaryl group containing one heteroatom.

[0279] In some embodiments, R 12 It is a 6-membered heteroaryl group containing 2 heteroatoms.

[0280] In some embodiments, R12 It is a 6-membered heteroaryl group containing 3 heteroatoms.

[0281] In some embodiments, R 12 It is a 5-membered heteroaryl group containing one heteroatom selected from N, O, or S.

[0282] In some embodiments, R 12 It is a 5-membered heteroaryl group containing two heteroatoms independently selected from N, O, and S.

[0283] In some embodiments, R 12 It is a 5-membered heteroaryl group containing 3 heteroatoms independently selected from N, O, and S.

[0284] In some embodiments, R 12 It is a 6-membered heteroaryl group containing one heteroatom selected from N, O, or S.

[0285] In some embodiments, R 12 It is a 6-membered heteroaryl group containing two heteroatoms independently selected from N, O, and S.

[0286] In some embodiments, R 12 It is a 6-membered heteroaryl group containing 3 heteroatoms independently selected from N, O, and S.

[0287] In some embodiments, R 12 It is a heteroatom containing one selected from N, O, or S, surrounded by an R 16 Substituted 5-membered heteroaryl group.

[0288] In some embodiments, R 12 It is a compound containing two heteroatoms independently selected from N, O, and S, bounded by an R. 16 Substituted 5-membered heteroaryl group.

[0289] In some embodiments, R 12 It is a compound containing three heteroatoms independently selected from N, O, and S, bounded by an R. 16 Substituted 5-membered heteroaryl group.

[0290] In some embodiments, R 12 It is a heteroatom containing one selected from N, O, or S, surrounded by an R 16 Substituted 6-membered heteroaryl group.

[0291] In some embodiments, R 12 It is a compound containing two heteroatoms independently selected from N, O, and S, bounded by an R. 16 Substituted 6-membered heteroaryl group.

[0292] In some embodiments, R 12 It is a compound containing three heteroatoms independently selected from N, O, and S, bounded by an R.16 Substituted 6-membered heteroaryl group.

[0293] In some embodiments, R 12 yes

[0294] In some embodiments, R 12 yes

[0295] In some embodiments, R 12 yes

[0296] In some embodiments, R 12 yes

[0297] In some embodiments, R 12 yes

[0298] In some embodiments, R 12 yes

[0299] In some embodiments, R 12 yes

[0300] In some embodiments, R 12 yes

[0301] In some embodiments, R 12 yes

[0302] In some embodiments, R 12 yes

[0303] In some embodiments, each R 13 It is independently selected from halogens, -OH, -CN, -C1-C6 alkyl, and -C1-C6 haloalkyl.

[0304] In some embodiments, R 13 It is a -C1-C6 alkyl group.

[0305] In some embodiments, the compound of formula (I) comprises two R groups as -C1-C6 alkyl groups. 13 .

[0306] In some embodiments, the compound of formula (I) comprises two R groups as methyl groups. 13 .

[0307] In some embodiments, two R 13Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl.

[0308] In some embodiments, two R 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl group, wherein the cycloalkyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl.

[0309] In some embodiments, two R 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 6-membered aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl.

[0310] In some embodiments, two R 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl.

[0311] In some embodiments, two R 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-6 membered heteroaryl group, wherein the heteroaryl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl.

[0312] In some embodiments, two R 13 Together with the atoms it is attached to and any intermediate atoms, it forms

[0313] In some embodiments, R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl.

[0314] In some embodiments, R 14 and R 15 Each is H.

[0315] In some embodiments, R 14 and R 15 Each is a methyl group.

[0316] In some embodiments, R 14and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups.

[0317] In some embodiments, each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 Cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, and C1-C6 haloalkyl.

[0318] In some embodiments, R 16 It is halogen.

[0319] In some embodiments, R 16 It is F.

[0320] In some embodiments, R 16 It is Cl.

[0321] In some embodiments, R 16 It is a C1-C6 alkyl group.

[0322] In some embodiments, R 16 It is a methyl group.

[0323] In some embodiments, R 16 It is an ethyl group.

[0324] In some embodiments, R 16 It is propyl.

[0325] In some embodiments, R 16 It's n-propyl.

[0326] In some embodiments, R 16 It is isopropyl.

[0327] In some embodiments, R 16 It is a C1-C6 alkoxy group.

[0328] In some embodiments, R 16 It is a methoxy group.

[0329] In some embodiments, R16 It is -C(O)R 14 .

[0330] In some embodiments, R 16 It is -C(O)CH3.

[0331] In some embodiments, X is selected from hydrogen, deuterium, halogen, OH, CN, NO2, and CONR. 14 R 15 C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted with cycloalkyl, heterocyclic, aryl and heteroaryl.

[0332] In some embodiments, X is -CN.

[0333] In some embodiments, X is CONR 14 R 15 .

[0334] In some embodiments, X is CONH2.

[0335] In some embodiments, X is selected from C1-C6 alkyl groups optionally substituted with cycloalkyl, heterocyclic, aryl, and heteroaryl groups.

[0336] In some embodiments, X is selected from C1-C6 alkyl groups substituted with heterocyclic groups.

[0337] In some embodiments, X is

[0338] In some embodiments, X is

[0339] In some embodiments, R M Selected from

[0340] In some embodiments, R M yes

[0341] In some embodiments, R M yes

[0342] In some embodiments, M is selected from 5-10-membered heterocyclic groups or 5-10-membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace.

[0343] In some embodiments, M is optionally represented by one or more R 16 Substituted 5-10 membered heterocyclic groups.

[0344] In some embodiments, M is optionally represented by one or more R 16 Substituted 5-10 heteroaryl groups.

[0345] In some embodiments, M is

[0346] In some embodiments, M is

[0347] In some embodiments, M is

[0348] In some embodiments, M is

[0349] In some embodiments, M is

[0350] In some embodiments, M is

[0351] In some embodiments, M is

[0352] In some embodiments, M is

[0353] In some embodiments, M is

[0354] In some embodiments, M is

[0355] In some embodiments, M is

[0356] In some embodiments, M is

[0357] In some embodiments, M is

[0358] In some embodiments, M is

[0359] In some embodiments, M is

[0360] In some embodiments, M is

[0361] In some embodiments, M is

[0362] In some embodiments, M is

[0363] In some embodiments, m is an integer selected from 0 and 1.

[0364] In some embodiments, m is 0.

[0365] In some embodiments, m is 1.

[0366] In some embodiments, the compound comprises formula (II): (ii), Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0367] In some embodiments, the compound comprises formula (I-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0368] In some embodiments, the compound comprises formula (III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0369] In some embodiments, the compound comprises formula (II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0370] In some embodiments, the compound comprises formula (I-II-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0371] In some embodiments, the compound comprises formula (I-II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0372] In some embodiments, the compound comprises formula (IIIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0373] In some embodiments, the compound comprises formula (IIIAI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4, and all other variables are as defined in this invention.

[0374] In some embodiments, the compound comprises formula (IIIAIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0375] In some embodiments, the compound comprises formula (IIIAI-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0376] In some embodiments, the compound comprises formula (IIIAI-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0377] In some embodiments, the compound comprises formula (IIIAI-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0378] In some embodiments, the compound comprises the formula (IIIAI-1-A*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0379] In some embodiments, the compound comprises the formula (IIIAI-1-A**): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0380] In some embodiments, the compound comprises the formula (IAI-1-A***): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0381] In some embodiments, the compound comprises the formula (IIIAI-1-A****): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0382] In some embodiments, the compound comprises the formula (IIIAI-1-Aa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0383] In some embodiments, the compound comprises the formula (IIIAI-1-Aa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0384] In some embodiments, the compound comprises the formula (IIIAI-1-Aa**): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0385] In some embodiments, the compound comprises the formula (IIIAI-1-Aa***): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0386] In some embodiments, the compound comprises the formula (IIIAI-1-Aa****): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0387] In some embodiments, the compound comprises formula (IIIAIa-1-A-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0388] In some embodiments, the compound comprises the formula (IIIAIa-1-A-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0389] In some embodiments, the compound comprises the formula (IIIAIa-1-A-1-H): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0390] In some embodiments, the compound comprises the formula (IIIAI-1-A-1-Ha): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0391] In some embodiments, the compound comprises formula (II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0392] In some embodiments, the compound comprises formula (II-II-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0393] In some embodiments, the compound comprises formula (II-II-Ia): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0394] In some embodiments, the compound comprises formula (II-II-Ia-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0395] In some embodiments, the compound comprises formula (II-II-Ia-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0396] In some embodiments, the compound comprises the formula (II-II-Ia-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0397] In some embodiments, the compound comprises the formula (II-II-Ia-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0398] In some embodiments, the compound comprises the formula (II-II-Ia-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0399] In some embodiments, the compound comprises formula (II-II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0400] In some embodiments, the compound comprises formula (II-II-II-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0401] In some embodiments, the compound comprises formula (II-II-II-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0402] In some embodiments, the compound comprises formula (II-II-II-a-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0403] In some embodiments, the compound comprises formula (II-II-II-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0404] In some embodiments, the compound comprises formula (II-II-II-a-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0405] In some embodiments, the compound comprises formula (II-II-II-a-2-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0406] In some embodiments, the compound comprises formula (II-II-II-a-2-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0407] In some embodiments, the compound comprises the formula (II-II-II-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0408] In some embodiments, the compound comprises the formula (II-II-II-a-2-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0409] In some embodiments, the compound comprises the formula (II-II-II-a-1-BI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0410] In some embodiments, the compound comprises the formula (II-II-II-a-2-BI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0411] In some embodiments, the compound comprises the formula (II-II-II-a-1-A-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0412] In some embodiments, the compound comprises the formula (II-II-II-a-2-A-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0413] In some embodiments, the compound comprises the formula (II-II-II-a-1-B-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0414] In some embodiments, the compound comprises the formula (II-II-II-a-2-B-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0415] In some embodiments, the compound comprises formula (II-II-II-a-1-A-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0416] In some embodiments, the compound comprises formula (II-II-II-a-2-A-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0417] In some embodiments, the compound comprises formula (II-II-II-a-1-B-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0418] In some embodiments, the compound comprises formula (II-II-II-a-2-B-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0419] In some embodiments, the compound comprises formula (II-II-II-a-1-A-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0420] In some embodiments, the compound comprises formula (II-II-II-a-2-A-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0421] In some embodiments, the compound comprises formula (II-II-II-a-1-B-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0422] In some embodiments, the compound comprises formula (II-II-II-a-2-B-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0423] In some embodiments, the compound comprises the formula (II-II-II-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0424] In some embodiments, the compound comprises the formula (II-II-II-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0425] In some embodiments, the compound comprises formula (II-II-II-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0426] In some embodiments, the compound comprises formula (II-II-II-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0427] In some embodiments, the compound comprises formula (II-II-II-b-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0428] In some embodiments, the compound comprises the formula (II-II-II-b-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0429] In some embodiments, the compound comprises the formula (II-II-II-b-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0430] In some embodiments, the compound comprises the formula (II-II-II-b-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0431] In some embodiments, the compound comprises formula (II-II-II-c): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0432] In some embodiments, the compound comprises formula (II-II-II-c-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0433] In some embodiments, the compound comprises formula (II-II-II-c-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0434] In some embodiments, the compound comprises the formula (II-II-II-c-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0435] In some embodiments, the compound comprises the formula (II-II-II-c-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0436] In some embodiments, the compound comprises the formula (II-II-II-c-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0437] In some embodiments, the compound comprises formula (II-II-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, 5; W is selected from O, S, S(O), S(O)2, NR 16 ';R 16 'Selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, -C(O)C1-C6 alkyl, and other variables as defined in this invention.

[0438] In some embodiments, the compound comprises formula (II-II-III-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0439] In some embodiments, the compound comprises formula (II-II-III-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0440] In some embodiments, the compound comprises formula (II-II-III-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0441] In some embodiments, the compound comprises the formula (II-II-III-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0442] In some embodiments, the compound comprises the formula (II-II-III-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0443] In some embodiments, the compound comprises the formula (II-II-III-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0444] In some embodiments, the compound comprises formula (II-II-III-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0445] In some embodiments, the compound comprises formula (II-II-III-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0446] In some embodiments, the compound comprises formula (II-II-III-b-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0447] In some embodiments, the compound comprises the formula (II-II-III-b-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0448] In some embodiments, the compound comprises the formula (II-II-III-b-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0449] In some embodiments, the compound comprises the formula (II-II-III-b-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0450] In some embodiments, the compound comprises formula (II-II-III-c): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0451] In some embodiments, the compound comprises formula (II-II-III-c-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0452] In some embodiments, the compound comprises formula (II-II-III-c-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0453] In some embodiments, the compound comprises the formula (II-II-III-c-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0454] In some embodiments, the compound comprises the formula (II-II-III-c-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0455] In some embodiments, the compound comprises the formula (II-II-III-c-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0456] In some embodiments, the compound comprises formula (II-II-III-d): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0457] In some embodiments, the compound comprises formula (II-II-III-d-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0458] In some embodiments, the compound comprises formula (II-II-III-d-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0459] In some embodiments, the compound comprises the formula (II-II-III-d-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0460] In some embodiments, the compound comprises the formula (II-II-III-d-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0461] In some embodiments, the compound comprises the formula (II-II-III-d-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0462] In some embodiments, the compound comprises formula (II-II-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4; W is selected from O, S, S(O), S(O)2, NR 16 ';R 16 'Selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, -C(O)C1-C6 alkyl, and other variables as defined in this invention.

[0463] In some embodiments, the compound comprises formula (II-II-IV-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0464] In some embodiments, the compound comprises formula (II-II-IV-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0465] In some embodiments, the compound comprises formula (II-II-IV-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0466] In some embodiments, the compound comprises the formula (II-II-IV-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0467] In some embodiments, the compound comprises the formula (II-II-IV-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0468] In some embodiments, the compound comprises the formula (II-II-IV-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0469] In some embodiments, the compound comprises formula (II-II-IV-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0470] In some embodiments, the compound comprises formula (II-II-IV-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0471] In some embodiments, the compound comprises formula (II-II-IV-b-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0472] In some embodiments, the compound comprises the formula (II-II-IV-b-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0473] In some embodiments, the compound comprises the formula (II-II-IV-b-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0474] In some embodiments, the compound comprises the formula (II-II-IV-b-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0475] In some embodiments, the compound comprises formula (II-II-IV-c): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0476] In some embodiments, the compound comprises formula (II-II-IV-c-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0477] In some embodiments, the compound comprises formula (II-II-IV-c-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0478] In some embodiments, the compound comprises the formula (II-II-IV-c-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0479] In some embodiments, the compound comprises the formula (II-II-IV-c-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0480] In some embodiments, the compound comprises the formula (II-II-IV-c-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0481] In some embodiments, the compound comprises formula (II-II-IV-d): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0482] In some embodiments, the compound comprises formula (II-II-IV-d-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0483] In some embodiments, the compound comprises formula (II-II-IV-d-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0484] In some embodiments, the compound comprises the formula (II-II-IV-d-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0485] In some embodiments, the compound comprises the formula (II-II-IV-d-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0486] In some embodiments, the compound comprises the formula (II-II-IV-d-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0487] In some embodiments, the compound comprises formula (II-II-V): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0488] In some embodiments, the compound comprises the formula (II-II-Va): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0489] In some embodiments, the compound comprises formula (II-II-Va-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0490] In some embodiments, the compound comprises formula (II-II-Va-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0491] In some embodiments, the compound comprises the formula (II-II-Va-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0492] In some embodiments, the compound comprises the formula (II-II-Va-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0493] In some embodiments, the compound comprises the formula (II-II-Va-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0494] In some embodiments, the compound comprises formula (II-II-VI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, 4, and all other variables are as defined in this invention.

[0495] In some embodiments, the compound comprises formula (II-II-VI-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0496] In some embodiments, the compound comprises formula (II-II-VI-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0497] In some embodiments, the compound comprises formula (II-II-VI-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0498] In some embodiments, the compound comprises formula (II-II-VI-a-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0499] In some embodiments, the compound comprises the formula (II-II-VI-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0500] In some embodiments, the compound comprises the formula (II-II-VI-a-1-A-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0501] In some embodiments, the compound comprises formula (II-II-VI-a-1-A-III): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0502] In some embodiments, the compound comprises formula (II-II-VI-a-1-A-IV): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0503] In some embodiments, the compound comprises the formula (II-II-VI-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0504] In some embodiments, the compound comprises the formula (II-II-VI-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0505] In some embodiments, the compound comprises formula (II-II-VI-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0506] In some embodiments, the compound comprises formula (II-II-VI-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0507] In some embodiments, the compound comprises formula (II-II-VI-b-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0508] In some embodiments, the compound comprises the formula (II-II-VI-b-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0509] In some embodiments, the compound comprises the formula (II-II-VI-b-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0510] In some embodiments, the compound comprises the formula (II-II-VI-b-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0511] In some embodiments, the compound comprises formula (II-II-VI-c): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0512] In some embodiments, the compound comprises formula (II-II-VI-c-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0513] In some embodiments, the compound comprises formula (II-II-VI-c-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0514] In some embodiments, the compound comprises the formula (II-II-VI-c-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0515] In some embodiments, the compound comprises the formula (II-II-VI-c-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0516] In some embodiments, the compound comprises the formula (II-II-VI-c-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0517] In some embodiments, the compound comprises formula (II-II-VI-d): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0518] In some embodiments, the compound comprises formula (II-II-VI-d-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0519] In some embodiments, the compound comprises formula (II-II-VI-d-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0520] In some embodiments, the compound comprises the formula (II-II-VI-d-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0521] In some embodiments, the compound comprises the formula (II-II-VI-d-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0522] In some embodiments, the compound comprises the formula (II-II-VI-d-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0523] In some embodiments, the compound comprises formula (II-II-VI-e): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0524] In some embodiments, the compound comprises formula (II-II-VI-e-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0525] In some embodiments, the compound comprises formula (II-II-VI-e-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0526] In some embodiments, the compound comprises the formula (II-II-VI-e-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0527] In some embodiments, the compound comprises the formula (II-II-VI-e-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0528] In some embodiments, the compound comprises the formula (II-II-VI-e-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0529] In some embodiments, the compound comprises formula (II-II-VI-f): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0530] In some embodiments, the compound comprises formula (II-II-VI-f-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0531] In some embodiments, the compound comprises formula (II-II-VI-f-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0532] In some embodiments, the compound comprises the formula (II-II-VI-f-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0533] In some embodiments, the compound comprises the formula (II-II-VI-f-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0534] In some embodiments, the compound comprises the formula (II-II-VI-f-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0535] In some embodiments, the compound comprises the formula (II-II-VI-g): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0536] In some embodiments, the compound comprises formula (II-II-VI-g-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0537] In some embodiments, the compound comprises the formula (II-II-VI-g-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0538] In some embodiments, the compound comprises the formula (II-II-VI-g-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0539] In some embodiments, the compound comprises the formula (II-II-VI-g-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0540] In some embodiments, the compound comprises the formula (II-II-VI-g-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0541] In some embodiments, the compound comprises formula (II-II-VI-h): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0542] In some embodiments, the compound comprises formula (II-II-VI-h-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0543] In some embodiments, the compound comprises the formula (II-II-VI-h-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0544] In some embodiments, the compound comprises the formula (II-II-VI-h-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0545] In some embodiments, the compound comprises the formula (II-II-VI-h-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0546] In some embodiments, the compound comprises the formula (II-II-VI-h-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0547] In some embodiments, the compound comprises formula (II-II-VI-i): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0548] In some embodiments, the compound comprises formula (II-II-VI-i-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0549] In some embodiments, the compound comprises formula (II-II-VI-i-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0550] In some embodiments, the compound comprises the formula (II-II-VI-i-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0551] In some embodiments, the compound comprises the formula (II-II-VI-i-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0552] In some embodiments, the compound comprises the formula (II-II-VI-i-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0553] In some embodiments, the compound comprises formula (II-II-VI-j): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0554] In some embodiments, the compound comprises formula (II-II-VI-j-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0555] In some embodiments, the compound comprises formula (II-II-VI-j-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0556] In some embodiments, the compound comprises the formula (II-II-VI-j-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0557] In some embodiments, the compound comprises the formula (II-II-VI-j-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0558] In some embodiments, the compound comprises the formula (II-II-VI-j-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0559] In some embodiments, the compound comprises formula (II-II-VI-k): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0560] In some embodiments, the compound comprises formula (II-II-VI-k-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0561] In some embodiments, the compound comprises the formula (II-II-VI-k-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0562] In some embodiments, the compound comprises the formula (II-II-VI-k-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0563] In some embodiments, the compound comprises the formula (II-II-VI-k-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0564] In some embodiments, the compound comprises the formula (II-II-VI-k-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0565] In some embodiments, the compound comprises formula (II-II-VI-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0566] In some embodiments, the compound comprises formula (II-II-VI-l-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0567] In some embodiments, the compound comprises formula (II-II-VI-l-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0568] In some embodiments, the compound comprises the formula (II-II-VI-l-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0569] In some embodiments, the compound comprises the formula (II-II-VI-l-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0570] In some embodiments, the compound comprises the formula (II-II-VI-l-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0571] In some embodiments, the compound comprises formula (II-II-VII): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, and other variables are as defined in this invention.

[0572] In some embodiments, the compound comprises formula (II-II-VII-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0573] In some embodiments, the compound comprises formula (II-II-VII-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0574] In some embodiments, the compound comprises formula (II-II-VII-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0575] In some embodiments, the compound comprises the formula (II-II-VII-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0576] In some embodiments, the compound comprises the formula (II-II-VII-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0577] In some embodiments, the compound comprises the formula (II-II-VII-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0578] In some embodiments, the compound comprises formula (II-II-VIII): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3, and all other variables are as defined in this invention.

[0579] In some embodiments, the compound comprises formula (II-II-VIII-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0580] In some embodiments, the compound comprises formula (II-II-VIII-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0581] In some embodiments, the compound comprises formula (II-II-VIII-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0582] In some embodiments, the compound comprises the formula (II-II-VIII-a-1-AI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0583] In some embodiments, the compound comprises the formula (II-II-VIII-a-1-AIa): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0584] In some embodiments, the compound comprises the formula (II-II-VIII-a-1-AIa*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0585] In some embodiments, the compound comprises formula (IAA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0586] In some embodiments, the compound comprises formula (IAA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0587] In some embodiments, the compound comprises formula (IAA-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0588] In some embodiments, the compound comprises formula (IAA-3):

[0589] Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0590] In some embodiments, the compound comprises formula (IAA-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0591] In some embodiments, the compound comprises formula (IAA-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0592] In some embodiments, the compound comprises formula (IAA-3-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0593] In some embodiments, the compound comprises formula (IAA-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0594] In some embodiments, the compound comprises formula (IAA-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0595] In some embodiments, the compound comprises formula (IAA-3-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0596] In some embodiments, the compound comprises the formula (IAA-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0597] In some embodiments, the compound comprises the formula (IAA-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0598] In some embodiments, the compound comprises the formula (IAA-3-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0599] In some embodiments, the compound comprises formula (IAA-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0600] In some embodiments, the compound comprises formula (IAA-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0601] In some embodiments, the compound comprises formula (IAA-3-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0602] In some embodiments, the compound comprises formula (IAA-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0603] In some embodiments, the compound comprises formula (IAA-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0604] In some embodiments, the compound comprises formula (IAA-3-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0605] In some embodiments, the compound comprises formula (IAA-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0606] In some embodiments, the compound comprises the formula (IAA-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0607] In some embodiments, the compound comprises formula (IAA-3-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0608] In some embodiments, the compound comprises formula (IAA-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0609] In some embodiments, the compound comprises formula (IAA-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0610] In some embodiments, the compound comprises formula (IAA-3-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0611] In some embodiments, the compound comprises formula (IAA-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0612] In some embodiments, the compound comprises formula (IAA-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0613] In some embodiments, the compound comprises formula (IAA-3-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0614] In some embodiments, the compound comprises formula (IAA-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0615] In some embodiments, the compound comprises the formula (IAA-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0616] In some embodiments, the compound comprises the formula (IAA-3-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0617] In some embodiments, the compound comprises formula (IAA-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0618] In some embodiments, the compound comprises formula (IAA-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0619] In some embodiments, the compound comprises formula (IAA-3-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0620] In some embodiments, the compound comprises formula (IAA-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0621] In some embodiments, the compound comprises formula (IAA-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0622] In some embodiments, the compound comprises formula (IAA-3-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0623] In some embodiments, the compound comprises the formula (IAA-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0624] In some embodiments, the compound comprises the formula (IAA-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0625] In some embodiments, the compound comprises the formula (IAA-3-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0626] In some embodiments, the compound comprises formula (IAB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0627] In some embodiments, the compound comprises formula (IAB-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0628] In some embodiments, the compound comprises formula (IAB-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0629] In some embodiments, the compound comprises formula (IAB-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0630] In some embodiments, the compound comprises formula (IAB-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0631] In some embodiments, the compound comprises formula (IAB-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0632] In some embodiments, the compound comprises formula (IAB-3-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0633] In some embodiments, the compound comprises formula (IAB-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0634] In some embodiments, the compound comprises formula (IAB-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0635] In some embodiments, the compound comprises formula (IAB-3-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0636] In some embodiments, the compound comprises formula (IAB-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0637] In some embodiments, the compound comprises formula (IAB-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0638] In some embodiments, the compound comprises formula (IAB-3-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0639] In some embodiments, the compound comprises formula (IAB-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0640] In some embodiments, the compound comprises formula (IAB-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0641] In some embodiments, the compound comprises formula (IAB-3-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0642] In some embodiments, the compound comprises formula (IAB-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0643] In some embodiments, the compound comprises formula (IAB-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0644] In some embodiments, the compound comprises formula (IAB-3-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0645] In some embodiments, the compound comprises formula (IAB-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0646] In some embodiments, the compound comprises formula (IAB-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0647] In some embodiments, the compound comprises formula (IAB-3-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0648] In some embodiments, the compound comprises formula (IAB-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0649] In some embodiments, the compound comprises formula (IAB-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0650] In some embodiments, the compound comprises formula (IAB-3-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0651] In some embodiments, the compound comprises formula (IAB-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0652] In some embodiments, the compound comprises formula (IAB-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0653] In some embodiments, the compound comprises formula (IAB-3-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0654] In some embodiments, the compound comprises formula (IAB-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0655] In some embodiments, the compound comprises formula (IAB-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0656] In some embodiments, the compound comprises formula (IAB-3-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0657] In some embodiments, the compound comprises formula (IAB-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0658] In some embodiments, the compound comprises formula (IAB-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0659] In some embodiments, the compound comprises formula (IAB-3-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0660] In some embodiments, the compound comprises formula (IAB-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0661] In some embodiments, the compound comprises formula (IAB-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0662] In some embodiments, the compound comprises formula (IAB-3-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0663] In some embodiments, the compound comprises formula (IAB-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0664] In some embodiments, the compound comprises formula (IAB-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0665] In some embodiments, the compound comprises formula (IAB-3-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0666] In some embodiments, the compound comprises formula (IIIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0667] In some embodiments, the compound comprises formula (IIIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0668] In some embodiments, the compound comprises formula (IIIA-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0669] In some embodiments, the compound comprises formula (IIIA-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0670] In some embodiments, the compound comprises formula (IIIA-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0671] In some embodiments, the compound comprises formula (IIIA-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0672] In some embodiments, the compound comprises formula (IIIA-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0673] In some embodiments, the compound comprises formula (IIIA-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0674] In some embodiments, the compound comprises formula (IIIA-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0675] In some embodiments, the compound comprises formula (IIIA-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0676] In some embodiments, the compound comprises formula (IIIA-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0677] In some embodiments, the compound comprises formula (IIIA-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0678] In some embodiments, the compound comprises formula (IIIA-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0679] In some embodiments, the compound comprises formula (IIIA-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0680] In some embodiments, the compound comprises formula (IIIA-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0681] In some embodiments, the compound comprises formula (IIIA-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0682] In some embodiments, the compound comprises formula (IIIA-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0683] In some embodiments, the compound comprises formula (IIIA-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0684] In some embodiments, the compound comprises formula (IIIA-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0685] In some embodiments, the compound comprises formula (IIIA-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0686] In some embodiments, the compound comprises formula (IIIA-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0687] In some embodiments, the compound comprises formula (IIIA-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0688] In some embodiments, the compound comprises formula (IIIA-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0689] In some embodiments, the compound comprises formula (IIIA-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0690] In some embodiments, the compound comprises formula (IIIA-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0691] In some embodiments, the compound comprises formula (IIIA-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0692] In some embodiments, the compound comprises formula (IIIA-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0693] In some embodiments, the compound comprises formula (II-II-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0694] In some embodiments, the compound comprises formula (II-II-A-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0695] In some embodiments, the compound comprises formula (II-II-A-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0696] In some embodiments, the compound comprises formula (IAA-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0697] In some embodiments, the compound comprises formula (IAA-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0698] In some embodiments, the compound comprises formula (II-II-A-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0699] In some embodiments, the compound comprises formula (II-II-A-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0700] In some embodiments, the compound comprises the formula (II-II-A-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0701] In some embodiments, the compound comprises the formula (II-II-A-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0702] In some embodiments, the compound comprises formula (II-II-A-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0703] In some embodiments, the compound comprises formula (II-II-A-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0704] In some embodiments, the compound comprises formula (II-II-A-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0705] In some embodiments, the compound comprises formula (II-II-A-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0706] In some embodiments, the compound comprises the formula (II-II-A-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0707] In some embodiments, the compound comprises the formula (II-II-A-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0708] In some embodiments, the compound comprises formula (II-II-A-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0709] In some embodiments, the compound comprises formula (II-II-A-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0710] In some embodiments, the compound comprises formula (II-II-A-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0711] In some embodiments, the compound comprises formula (II-II-A-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0712] In some embodiments, the compound comprises the formula (II-II-A-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0713] In some embodiments, the compound comprises the formula (II-II-A-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0714] In some embodiments, the compound comprises formula (II-II-A-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0715] In some embodiments, the compound comprises formula (II-II-A-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0716] In some embodiments, the compound comprises formula (II-II-A-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0717] In some embodiments, the compound comprises formula (II-II-A-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0718] In some embodiments, the compound comprises the formula (II-II-A-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0719] In some embodiments, the compound comprises the formula (II-II-A-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0720] In some embodiments, the compound comprises formula (I-II-IA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0721] In some embodiments, the compound comprises formula (I-II-IA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0722] In some embodiments, the compound comprises formula (I-II-IA-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0723] In some embodiments, the compound comprises formula (I-II-IA-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0724] In some embodiments, the compound comprises formula (I-II-IA-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0725] In some embodiments, the compound comprises formula (I-II-IA-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0726] In some embodiments, the compound comprises formula (I-II-IA-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0727] In some embodiments, the compound comprises the formula (I-II-IA-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0728] In some embodiments, the compound comprises formula (I-II-IA-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0729] In some embodiments, the compound comprises formula (I-II-IA-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0730] In some embodiments, the compound comprises formula (I-II-IA-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0731] In some embodiments, the compound comprises formula (I-II-IA-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0732] In some embodiments, the compound comprises formula (I-II-IA-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0733] In some embodiments, the compound comprises formula (I-II-IA-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0734] In some embodiments, the compound comprises formula (I-II-IA-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0735] In some embodiments, the compound comprises formula (I-II-IA-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0736] In some embodiments, the compound comprises formula (I-II-IA-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0737] In some embodiments, the compound comprises formula (I-II-IA-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0738] In some embodiments, the compound comprises formula (I-II-IA-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0739] In some embodiments, the compound comprises formula (I-II-IA-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0740] In some embodiments, the compound comprises formula (I-II-IA-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0741] In some embodiments, the compound comprises formula (I-II-IA-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0742] In some embodiments, the compound comprises formula (I-II-IA-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0743] In some embodiments, the compound comprises formula (I-II-IA-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0744] In some embodiments, the compound comprises formula (I-II-IA-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0745] In some embodiments, the compound comprises formula (I-II-IA-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0746] In some embodiments, the compound comprises formula (I-II-IA-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0747] In some embodiments, the compound comprises formula (I-II-II-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0748] In some embodiments, the compound comprises formula (I-II-II-A-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0749] In some embodiments, the compound comprises formula (I-II-II-A-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0750] In some embodiments, the compound comprises the formula (I-II-II-AA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4; and all other variables are as defined in this invention.

[0751] In some embodiments, the compound comprises formula (I-II-II-A-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0752] In some embodiments, the compound comprises formula (I-II-II-A-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0753] In some embodiments, the compound comprises formula (I-II-II-A-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0754] In some embodiments, the compound comprises formula (I-II-II-A-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0755] In some embodiments, the compound comprises the formula (I-II-II-A-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0756] In some embodiments, the compound comprises formula (I-II-II-A-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0757] In some embodiments, the compound comprises formula (I-II-II-A-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0758] In some embodiments, the compound comprises formula (I-II-II-A-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0759] In some embodiments, the compound comprises formula (I-II-II-A-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0760] In some embodiments, the compound comprises formula (I-II-II-A-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0761] In some embodiments, the compound comprises formula (I-II-II-A-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0762] In some embodiments, the compound comprises the formula (I-II-II-A-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0763] In some embodiments, the compound comprises formula (I-II-II-A-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0764] In some embodiments, the compound comprises formula (I-II-II-A-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0765] In some embodiments, the compound comprises formula (I-II-II-A-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0766] In some embodiments, the compound comprises formula (I-II-II-A-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0767] In some embodiments, the compound comprises the formula (I-II-II-A-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0768] In some embodiments, the compound comprises formula (I-II-II-A-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0769] In some embodiments, the compound comprises formula (I-II-II-A-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0770] In some embodiments, the compound comprises formula (I-II-II-A-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0771] In some embodiments, the compound comprises formula (I-II-II-A-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0772] In some embodiments, the compound comprises formula (I-II-II-A-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0773] In some embodiments, the compound comprises formula (I-II-II-A-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0774] In some embodiments, the compound comprises the formula (I-II-II-A-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0775] In some embodiments, the compound comprises formula (II-II-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0776] In some embodiments, the compound comprises formula (II-II-B-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0777] In some embodiments, the compound comprises formula (II-II-B-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0778] In some embodiments, the compound comprises formula (II-II-B-1-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0779] In some embodiments, the compound comprises formula (II-II-B-2-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0780] In some embodiments, the compound comprises formula (II-II-B-1-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0781] In some embodiments, the compound comprises formula (II-II-B-2-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0782] In some embodiments, the compound comprises the formula (II-II-B-1-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0783] In some embodiments, the compound comprises formula (II-II-B-2-1-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0784] In some embodiments, the compound comprises formula (II-II-B-1-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0785] In some embodiments, the compound comprises formula (II-II-B-2-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0786] In some embodiments, the compound comprises formula (II-II-B-1-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0787] In some embodiments, the compound comprises formula (II-II-B-2-2-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0788] In some embodiments, the compound comprises formula (II-II-B-1-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0789] In some embodiments, the compound comprises the formula (II-II-B-2-2-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0790] In some embodiments, the compound comprises formula (II-II-B-1-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0791] In some embodiments, the compound comprises formula (II-II-B-2-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0792] In some embodiments, the compound comprises formula (II-II-B-1-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0793] In some embodiments, the compound comprises formula (II-II-B-2-3-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0794] In some embodiments, the compound comprises formula (II-II-B-1-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0795] In some embodiments, the compound comprises the formula (II-II-B-2-3-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0796] In some embodiments, the compound comprises formula (II-II-B-1-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0797] In some embodiments, the compound comprises formula (II-II-B-2-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0798] In some embodiments, the compound comprises formula (II-II-B-1-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0799] In some embodiments, the compound comprises formula (II-II-B-2-4-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0800] In some embodiments, the compound comprises formula (II-II-B-1-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0801] In some embodiments, the compound comprises the formula (II-II-B-2-4-a*): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0802] In some embodiments, the compound comprises formula (IGA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0803] In some embodiments, the compound comprises the formula (IGBG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl or a C3-C7 cycloalkyl, optionally substituted with one or more halogens.

[0804] In some embodiments, the compound comprises formula (IGB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0805] In some embodiments, the compound comprises the formula (IGC): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0806] In some embodiments, the compound comprises the formula (IAADG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein H is a heteroatom comprising 1-3 heteroatoms selected from O, N, and S, optionally surrounded by one or more R atoms. 16 Substituted 5-6 aryl groups.

[0807] In some embodiments, the compound comprises the formula (IGD): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0808] In some embodiments, the compound comprises formula (IGE): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0809] In some embodiments, the compound comprises the formula (IGF): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0810] In some embodiments, the compound comprises the formula (IGG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0811] In some embodiments, the compound comprises the formula (IGH): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0812] In some embodiments, the compound comprises formula (IGJ): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0813] In some embodiments, the compound comprises the formula (IGK): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0814] In some embodiments, the compound comprises formula (IAAA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0815] In some embodiments, the compound comprises the formula (IAABG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0816] In some embodiments, the compound comprises formula (IAAB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0817] In some embodiments, the compound comprises the formula (IAAC): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0818] In some embodiments, the compound comprises the formula (IAADG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein H is a heteroatom comprising 1-3 heteroatoms selected from O, N, and S, optionally surrounded by one or more R atoms. 16 Substituted 5-6 aryl groups.

[0819] In some embodiments, the compound comprises formula (IAAD): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0820] In some embodiments, the compound comprises formula (IAAE): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0821] In some embodiments, the compound comprises formula (IAAF): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0822] In some embodiments, the compound comprises the formula (IAAG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0823] In some embodiments, the compound comprises the formula (IAAH): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0824] In some embodiments, the compound comprises formula (IAAJ): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0825] In some embodiments, the compound comprises formula (IAAK): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0826] In some embodiments, the compound comprises formula (II-II-AA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0827] In some embodiments, the compound comprises the formula (II-II-ABG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R sIt is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0828] In some embodiments, the compound comprises formula (II-II-ABG-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0829] In some embodiments, the compound comprises formula (II-II-ABG-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0830] In some embodiments, the compound comprises formula (II-II-ABG-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0831] In some embodiments, the compound comprises formula (II-II-ABG-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0832] In some embodiments, the compound comprises formula (II-II-ABG-5): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0833] In some embodiments, the compound comprises formula (II-II-ABG-6): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens.

[0834] In some embodiments, the compound comprises formula (II-II-ABG-7): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens, R g Selected from H, C1-C6 alkyl, and -C(O)-C1-C6 alkyl.

[0835] In some embodiments, the compound comprises formula (II-II-ABG-8): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, wherein R s It is a C1-C6 alkyl group optionally substituted with one or more halogens, R g Selected from H, C1-C6 alkyl, and -C(O)-C1-C6 alkyl.

[0836] In some embodiments, the compound comprises formula (II-II-AB-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0837] In some embodiments, the compound comprises formula (II-II-AC): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0838] In some embodiments, the compound comprises formula (II-II-AC-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0839] In some embodiments, the compound comprises the formula (II-II-ADG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein H is a heteroatom comprising 1-3 heteroatoms selected from O, N, and S, optionally surrounded by one or more R atoms. 16 Substituted 5-6 aryl groups.

[0840] In some embodiments, the compound comprises formula (II-II-ADG-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer thereof, wherein H is a heteroatom comprising 1-3 heteroatoms selected from O, N, and S, optionally surrounded by one or more R atoms. 16 Substituted 5-6 aryl groups.

[0841] In some embodiments, the compound comprises formula (II-II-AD): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0842] In some embodiments, the compound comprises formula (II-II-AD-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0843] In some embodiments, the compound comprises formula (II-II-AE): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0844] In some embodiments, the compound comprises formula (II-II-AE-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0845] In some embodiments, the compound comprises formula (II-II-AF): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0846] In some embodiments, the compound comprises formula (II-II-AF-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0847] In some embodiments, the compound comprises the formula (II-II-AG): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0848] In some embodiments, the compound comprises formula (II-II-AG-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0849] In some embodiments, the compound comprises the formula (II-II-AH): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0850] In some embodiments, the compound comprises formula (II-II-AH-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0851] In some embodiments, the compound comprises formula (II-II-AJ): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0852] In some embodiments, the compound comprises formula (II-II-AJ-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0853] In some embodiments, the compound comprises formula (II-II-AK): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0854] In some embodiments, the compound comprises formula (II-II-AK-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[0855] In some embodiments, the compound of formula (I) is any combination of fragments (1), (2) and (3) presented in Table 1.

[0856] Table 1: A list of fragments (1), (2), and (3) that give the structure of the compound of formula (I) by combining any fragment (1) with any fragment (2) and any fragment (3).

[0857] In some embodiments, the compound comprises formula (II-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0858] In some embodiments, the compound comprises formula (II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0859] In some embodiments, the compound comprises formula (II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0860] In some embodiments, the compound comprises formula (II-I-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0861] In some embodiments, the compound comprises formula (II-II-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0862] In some embodiments, the compound comprises formula (II-II-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0863] In some embodiments, the compound comprises formula (II-IIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0864] In some embodiments, the compound comprises formula (II-IIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0865] In some embodiments, the compound comprises formula (II-I-II-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0866] In some embodiments, the compound comprises formula (II-I-II-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0867] In some embodiments, the compound comprises formula (II-II-IA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0868] In some embodiments, the compound comprises formula (II-II-IB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0869] In some embodiments, the compound comprises formula (II-II-II-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0870] In some embodiments, the compound comprises formula (II-II-II-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0871] In some embodiments, the compound comprises formula (II-IIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0872] In some embodiments, the compound comprises formula (II-IIB-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0873] In some embodiments, the compound comprises formula (II-I-II-A-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0874] In some embodiments, the compound comprises formula (II-I-II-B-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0875] In some embodiments, the compound comprises formula (II-II-IA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0876] In some embodiments, the compound comprises formula (II-II-IB-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0877] In some embodiments, the compound comprises formula (II-II-II-A-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0878] In some embodiments, the compound comprises formula (II-II-II-B-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0879] In some embodiments, the compound comprises formula (II-IIA-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0880] In some embodiments, the compound comprises formula (II-IIB-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0881] In some embodiments, the compound comprises formula (II-I-II-A-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0882] In some embodiments, the compound comprises formula (II-I-II-B-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0883] In some embodiments, the compound comprises formula (II-II-IA-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0884] In some embodiments, the compound comprises formula (II-II-IB-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0885] In some embodiments, the compound comprises formula (II-II-II-A-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0886] In some embodiments, the compound comprises formula (II-II-II-B-1-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0887] In some embodiments, the compound comprises the formula (II-IIA-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0888] In some embodiments, the compound comprises the formula (II-IIB-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0889] In some embodiments, the compound comprises the formula (II-I-II-A-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0890] In some embodiments, the compound comprises the formula (II-I-II-B-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0891] In some embodiments, the compound comprises the formula (II-II-IA-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0892] In some embodiments, the compound comprises the formula (II-II-IB-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0893] In some embodiments, the compound comprises the formula (II-II-II-A-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0894] In some embodiments, the compound comprises the formula (II-II-II-B-1-aI): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0895] In some embodiments, the compound comprises formula (II-IIA-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0896] In some embodiments, the compound comprises formula (II-IIB-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0897] In some embodiments, the compound comprises the formula (II-I-II-A-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0898] In some embodiments, the compound comprises the formula (II-I-II-B-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0899] In some embodiments, the compound comprises the formula (II-II-IA-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0900] In some embodiments, the compound comprises the formula (II-II-IB-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0901] In some embodiments, the compound comprises the formula (II-II-II-A-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0902] In some embodiments, the compound comprises the formula (II-II-II-B-1-aIA): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0903] In some embodiments, the compound comprises the formula (II-IIA-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0904] In some embodiments, the compound comprises formula (II-IIB-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0905] In some embodiments, the compound comprises the formula (II-I-II-A-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0906] In some embodiments, the compound comprises formula (II-I-II-B-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0907] In some embodiments, the compound comprises the formula (II-II-IA-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0908] In some embodiments, the compound comprises the formula (II-II-IB-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0909] In some embodiments, the compound comprises the formula (II-II-II-A-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0910] In some embodiments, the compound comprises formula (II-II-II-B-1-aIA-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0911] In some embodiments, the compound comprises the formula (II-IIA-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4; and all other variables are as defined in this invention.

[0912] In some embodiments, the compound comprises the formula (II-IIB-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein K is selected from O, NH, S; y is an integer selected from 0, 1 and 2; and all other variables are as defined in this invention.

[0913] In some embodiments, the compound comprises the formula (II-I-II-A-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4; and all other variables are as defined in this invention.

[0914] In some embodiments, the compound comprises the formula (II-I-II-B-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein K is selected from O, NH, S; y is an integer selected from 0, 1 and 2; and all other variables are as defined in this invention.

[0915] In some embodiments, the compound comprises the formula (II-II-IA-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4; and all other variables are as defined in this invention.

[0916] In some embodiments, the compound comprises the formula (II-II-IB-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein K is selected from O, NH, S; y is an integer selected from 0, 1 and 2; and all other variables are as defined in this invention.

[0917] In some embodiments, the compound comprises the formula (II-II-II-A-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein x is an integer selected from 0, 1, 2, 3 and 4; and all other variables are as defined in this invention.

[0918] In some embodiments, the compound comprises the formula (II-II-II-B-1-aIB): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof, wherein all variables are as defined in this invention.

[0919] In some embodiments, the compound of formula (II) is any combination of fragments (1), (2) and (3) presented in Table 2.

[0920] Table 2: A list of fragments (1), (2), and (3) that give the structure of the compound of formula (II) by combining any fragment (1) with any fragment (2) and any fragment (3).

[0921] In some embodiments, the compound comprises formula (A'): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; R M Selected from M is selected from 5-10 membered heterocyclic groups or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; C is a ring selected from cycloalkyl, aryl, heterocyclic, or heteroaryl groups; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups.16 replace; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; Or R 2 and R 3 Together they form a double bond; R 5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN; R 12Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; n is an integer selected from 0, 1, and 2; m is an integer selected from 0 and 1; x is an integer selected from 0, 1, 2, 3, and 4.

[0922] In some embodiments, the compound comprises formula (I'): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; C is a ring selected from cycloalkyl, aryl, heterocyclic, or heteroaryl groups; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; Or R 2 and R 3 Together they form a double bond; R 5Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; R 9 R 10 R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, and -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl group is optionally surrounded by one or more R 16 replace; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; n is an integer selected from 0, 1, and 2; x is an integer selected from 0, 1, 2, 3, and 4.

[0923] In some embodiments, the compound comprises formula (II'): Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer. in: Each R N Independently selected from H, C1-C6 alkyl, and cycloalkyl; Q is CR 5 R Q or NR Q ; R q It is H; R Q It is R N ;or R q and R Q Together they form bonds; M is selected from 5-10 membered heterocyclic groups or 5-10 membered heteroaryl groups, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; C is a ring selected from cycloalkyl, aryl, heterocyclic, or heteroaryl groups; R 2 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; R 3 The group is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally separated by one or more R groups. 16 replace; Or R 2 and R 3 Together they form a double bond; R 5 Selected from hydrogen, halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)N-NR 14 R 15 cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein the alkyl, alkenyl, alkoxy, cycloalkyl, aryl, heterocyclic, or heteroaryl group is optionally surrounded by one or more R groups. 16 replace; Each R 6 Independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl, or aryl group is optionally separated by one or more R groups. 16 replace; R 7 Selected from -(CH2) n Aryl group, wherein the aryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, -NO2, -NR. 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; R 8 Selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclic and heteroaryl; Or R 7 and R 8 Together with the atoms it is attached to and any intermediate atoms, it forms a group optionally bounded by one or more R atoms. 13 Substituted 5-7 member monocyclic or bicyclic heterocyclic groups; Each R 13 Independently selected from halogens, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two Rs 13 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, and cycloalkyl; Or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group that is optionally substituted with one or more halogens, -OH, -CN, or C1-C6 alkyl groups; Each R 16 Independently selected from halogens, -OH, -CN, -NO2, -NR 14 R 15 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 -C(O)R 14 -C(O)N-NR 14 R15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted by one or more substituents independently selected from: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two Rs 16 Together with the atoms to which it is attached and any intermediate atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocyclic or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocyclic or heteroaryl is optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl group is optionally substituted by cycloalkyl, heterocyclic, aryl and heteroaryl; m is an integer selected from 0 and 1; n is an integer selected from 0, 1, and 2; x is an integer selected from 0, 1, 2, 3, and 4.

[0924] In some embodiments, the compound comprises formula (A'-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0925] In some embodiments, the compound comprises formula (A'-Ia): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0926] In some embodiments, the compound comprises formula (A'-Ib): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0927] In some embodiments, the compound comprises formula (A'-Ia-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0928] In some embodiments, the compound comprises the formula (A'-Ia-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0929] In some embodiments, the compound comprises formula (A'-Ia-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0930] In some embodiments, the compound comprises formula (A'-Ia-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0931] In some embodiments, the compound comprises formula (A'-Ia-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0932] In some embodiments, the compound comprises the formula (A'-Ia-3-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0933] In some embodiments, the compound comprises formula (A'-Ia-3-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0934] In some embodiments, the compound comprises formula (A'-Ia-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0935] In some embodiments, the compound comprises the formula (A'-Ia-4-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0936] In some embodiments, the compound comprises formula (A'-Ia-4-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0937] In some embodiments, the compound comprises formula (A'-Ia-5): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein each U is independently selected from CH and N, and at least one U is N; x is an integer selected from 0 to (a number of 4-N); and all other variables are as defined in this invention.

[0938] In some embodiments, the compound comprises the formula (A'-Ia-5-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0939] In some embodiments, the compound comprises formula (A'-Ia-5-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0940] In some embodiments, the compound comprises the formula (A'-Ia-5-C): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0941] In some embodiments, the compound comprises the formula (A'-Ia-5-D): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0942] In some embodiments, the compound comprises formula (A'-Ib-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0943] In some embodiments, the compound comprises the formula (A'-Ib-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0944] In some embodiments, the compound comprises formula (A'-Ib-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0945] In some embodiments, the compound comprises the formula (A'-Ib-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0946] In some embodiments, the compound comprises formula (A'-Ib-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0947] In some embodiments, the compound comprises the formula (A'-Ib-3-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0948] In some embodiments, the compound comprises formula (A'-Ib-3-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0949] In some embodiments, the compound comprises formula (A'-Ib-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0950] In some embodiments, the compound comprises the formula (A'-Ib-4-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0951] In some embodiments, the compound comprises formula (A'-Ib-4-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0952] In some embodiments, the compound comprises formula (A'-Ib-5): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein each U is independently selected from CH and N, and at least one U is N; x is an integer selected from 0 to (a number of 4-N); and all other variables are as defined in this invention.

[0953] In some embodiments, the compound comprises the formula (A'-Ib-5-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0954] In some embodiments, the compound comprises formula (A'-Ib-5-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0955] In some embodiments, the compound comprises the formula (A'-Ib-5-C): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0956] In some embodiments, the compound comprises the formula (A'-Ib-5-D): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0957] In some embodiments, the compound comprises formula (A'-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0958] In some embodiments, the compound comprises formula (A'-II-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0959] In some embodiments, the compound comprises formula (A'-II-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0960] In some embodiments, the compound comprises formula (A'-II-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0961] In some embodiments, the compound comprises the formula (A'-II-a-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0962] In some embodiments, the compound comprises formula (A'-II-a-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0963] In some embodiments, the compound comprises formula (A'-II-a-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0964] In some embodiments, the compound comprises formula (A'-II-a-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0965] In some embodiments, the compound comprises the formula (A'-II-a-3-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0966] In some embodiments, the compound comprises formula (A'-II-a-3-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0967] In some embodiments, the compound comprises formula (A'-II-a-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0968] In some embodiments, the compound comprises the formula (A'-II-a-4-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0969] In some embodiments, the compound comprises formula (A'-II-a-4-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0970] In some embodiments, the compound comprises formula (A'-II-a-5): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein each U is independently selected from CH and N, and at least one U is N; x is an integer selected from 0 to (a number of 4-N); and all other variables are as defined in this invention.

[0971] In some embodiments, the compound comprises the formula (A'-II-a-5-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0972] In some embodiments, the compound comprises formula (A'-II-a-5-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0973] In some embodiments, the compound comprises the formula (A'-II-a-5-C): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0974] In some embodiments, the compound comprises the formula (A'-II-a-5-D): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0975] In some embodiments, the compound comprises formula (A'-II-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0976] In some embodiments, the compound comprises the formula (A'-II-b-1-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0977] In some embodiments, the compound comprises the formula (A'-II-b-1-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0978] In some embodiments, the compound comprises formula (A'-II-b-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0979] In some embodiments, the compound comprises formula (A'-II-b-3): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0980] In some embodiments, the compound comprises the formula (A'-II-b-3-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0981] In some embodiments, the compound comprises the formula (A'-II-b-3-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0982] In some embodiments, the compound comprises formula (A'-II-b-4): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0983] In some embodiments, the compound comprises the formula (A'-II-b-4-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0984] In some embodiments, the compound comprises the formula (A'-II-b-4-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein W is selected from O, NH, S, S(O), S(O)2, and all other variables are as defined in this invention.

[0985] In some embodiments, the compound comprises formula (A'-II-b-5): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein each U is independently selected from CH and N, and at least one U is N; x is an integer selected from 0 to (a number of 4-N); and all other variables are as defined in this invention.

[0986] In some embodiments, the compound comprises the formula (A'-II-b-5-A): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0987] In some embodiments, the compound comprises the formula (A'-II-b-5-B): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0988] In some embodiments, the compound comprises the formula (A'-II-b-5-C): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0989] In some embodiments, the compound comprises the formula (A'-II-b-5-D): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, wherein x is an integer selected from 0, 1, 2, and 3; and all other variables are as defined in this invention.

[0990] In some embodiments, the compound comprises formula (I'-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0991] In some embodiments, the compound comprises formula (I'-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0992] In some embodiments, the compound comprises formula (I'-Ia): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0993] In some embodiments, the compound comprises formula (I'-Ib): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0994] In some embodiments, the compound comprises formula (I'-II-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0995] In some embodiments, the compound comprises formula (I'-II-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0996] In some embodiments, the compound comprises formula (II'-I): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0997] In some embodiments, the compound comprises formula (II'-II): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0998] In some embodiments, the compound comprises formula (II'-Ia): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[0999] In some embodiments, the compound comprises formula (II'-Ib): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1000] In some embodiments, the compound comprises formula (II'-II-a): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1001] In some embodiments, the compound comprises formula (II'-II-b): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1002] In some embodiments, the compound comprises formula (II'-Ia-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1003] In some embodiments, the compound comprises formula (II'-Ia-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1004] In some embodiments, the compound comprises formula (II'-Ib-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1005] In some embodiments, the compound comprises formula (II'-Ib-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1006] In some embodiments, the compound comprises formula (II'-II-a-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1007] In some embodiments, the compound comprises formula (II'-II-a-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1008] In some embodiments, the compound comprises formula (II'-II-b-1): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1009] In some embodiments, the compound comprises formula (II'-II-b-2): Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof.

[1010] In some embodiments, the compound of formula (A) is a compound of formula (I).

[1011] In some embodiments, the compound of formula (A) is a compound of formula (II).

[1012] Suitable pharmaceutically acceptable salts of the compounds of the present invention are, for example, acid-addition salts of the compounds of the present invention having sufficient basicity, such as acid-addition salts with, for example, inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citrate methanesulfonate, or maleic acid. Alternatively, suitable pharmaceutically acceptable salts of the compounds of the present invention having sufficient acidity are alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; ammonium salts; or salts with organic bases providing pharmaceutically acceptable cations, such as salts with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine, or tri-(2-hydroxyethyl)amine.

[1013] It should be understood that compounds of any of the formulas disclosed in this invention and any pharmaceutically acceptable salt thereof comprise stereoisomers of said compounds, mixtures of stereoisomers, and polymorphs of all isomer forms.

[1014] In some embodiments, the compound is selected from the compounds described in Table 3 and their pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs, isotope derivatives, or tautomers.

[1015] In some embodiments, the compound is selected from the compounds described in Table 3, as well as their prodrugs and pharmaceutically acceptable salts.

[1016] In some embodiments, the compounds are selected from the compounds described in Table 3 and their pharmaceutically acceptable salts.

[1017] In some embodiments, the compound is selected from prodrugs of the compounds described in Table 3 and their pharmaceutically acceptable salts.

[1018] In some embodiments, the compound is selected from the compounds described in Table 3.

[1019] Table 3: Some examples of compounds of formula (A)

[1020] In some embodiments, the compound is a pharmaceutically acceptable salt of any of the compounds described in Table 3.

[1021] In some embodiments, the compound is a lithium, sodium, potassium, calcium, or magnesium salt of any of the compounds described in Table 3.

[1022] In some embodiments, the compound is a sodium or potassium salt of any of the compounds described in Table 3.

[1023] In some embodiments, the compound is a salt of any acid described in Table 4 and any of the compounds described in Table 3.

[1024] Table 4: Pharmaceutically acceptable acids that form salts with compounds of formula (A).

[1025] In some embodiments, the compound is a salt of acetic acid and any of the compounds described in Table 3.

[1026] In some embodiments, the compound is a salt of adipic acid and any of the compounds described in Table 3.

[1027] In some embodiments, the compound is a salt of ascorbic acid (L) and any of the compounds described in Table 3.

[1028] In some embodiments, the compound is a salt of hydrobromic acid and any of the compounds described in Table 3.

[1029] In some embodiments, the compound is a salt of hydrochloric acid and any of the compounds described in Table 3.

[1030] In some embodiments, the compound is a salt of citric acid and any of the compounds described in Table 3.

[1031] In some embodiments, the compound is a salt of glutamic acid and any of the compounds described in Table 3.

[1032] In some embodiments, the compound is a salt of oxalic acid and any of the compounds described in Table 3.

[1033] In some embodiments, the compound is a salt of formic acid and any of the compounds described in Table 3.

[1034] In some embodiments, the compound is a salt of sulfuric acid and any of the compounds described in Table 3.

[1035] In some aspects, the present invention provides a compound that is an isotopic derivative (e.g., an isotopically labeled compound) of any of the compounds of the formula disclosed herein.

[1036] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Table 3, as well as its prodrug and pharmaceutically acceptable salt.

[1037] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Table 3, and a pharmaceutically acceptable salt thereof.

[1038] In some embodiments, the compound is an isotopic derivative of any of the prodrugs of the compounds described in Table 3, and a pharmaceutically acceptable salt thereof.

[1039] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Table 3.

[1040] It should be understood that any of the various techniques recognized in the art can be used to prepare isotope derivatives. For example, isotope derivatives can generally be prepared by performing the procedures disclosed in the schemes and / or examples described in this invention using an isotopically labeled reagent instead of a non-isotopically labeled reagent.

[1041] In some embodiments, the isotope derivative is a deuterium-labeled compound.

[1042] In some embodiments, the isotope derivative is a deuterium-labeled compound of any of the compounds of the formula disclosed in this invention.

[1043] As used herein, the term "isotope derivative" refers to a derivative of a compound enriched or labeled with one or more atomic isotopes. For example, an isotope derivative of a compound of formula (A) is isotopically enriched with or labeled with one or more isotopes compared to the corresponding compound of formula (A). In some embodiments, the isotope derivative is isotopically enriched with or labeled with one or more isotopes selected from... 2 H, 13 C 14 C 15 N、 18 O、 29 Si、 31 P and 34 The atoms of S are enriched or labeled with one or more of the atoms. In some embodiments, the isotope derivative is a deuterium-labeled compound (i.e., deuterium-labeled relative to one or more of its atoms). 2 H enrichment).

[1044] In some embodiments, the compound is a deuterated compound of any of the compounds described in Table 3, as well as its prodrug and pharmaceutically acceptable salt.

[1045] In some embodiments, the compound is a deuterium-labeled compound of any of the compounds described in Table 3, and its pharmaceutically acceptable salt.

[1046] In some embodiments, the compound is a deuterated compound of any of the prodrugs of the compounds described in Table 3, and a pharmaceutically acceptable salt thereof.

[1047] In some embodiments, the compound is a deuterium-labeled compound of any of the compounds described in Table 3.

[1048] It should be understood that deuterium-labeled compounds contain deuterium atoms with a deuterium abundance substantially greater than the natural abundance of deuterium, which is 0.015%.

[1049] In some embodiments, the deuterium enrichment factor per deuterium atom of the deuterium-labeled compound is at least 3500 (52.5% deuterium inclusion at each deuterium atom), at least 4000 (60% deuterium inclusion), at least 4500 (67.5% deuterium inclusion), at least 5000 (75% deuterium inclusion), at least 5500 (82.5% deuterium inclusion), at least 6000 (90% deuterium inclusion), at least 6333.3 (95% deuterium inclusion), at least 6466.7 (97% deuterium inclusion), at least 6600 (99% deuterium inclusion), or at least 6633.3 (99.5% deuterium inclusion). As used herein, the term "deuterium enrichment factor" refers to the ratio between the deuterium abundance and the natural abundance of deuterium.

[1050] It should be understood that any of the various techniques recognized in the art can be used to prepare deuterium-labeled compounds. For example, deuterium-labeled compounds can generally be prepared by performing the procedures disclosed in the schemes and / or examples described in this invention by replacing the non-deuterium-labeled reagent with a deuterium-labeled reagent.

[1051] Compounds of the present invention containing the aforementioned deuterium atoms, or pharmaceutically acceptable salts or solvates thereof, are within the scope of the present invention. Additionally, deuterium (i.e., 2 H) substitution can provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirement).

[1052] In some embodiments, the compound is 18 F-labeled compounds.

[1053] In some embodiments, the compound is 33 S-labeled compounds,34 S-labeled compounds, 35 S-labeled compounds, 36 S-labeled compounds or any combination thereof.

[1054] It should be understood that any of the various techniques recognized in the art can be used to prepare... 18 F, 33 S, 34 S, 35 S and / or 36 S-labeled compounds. For example, deuterium-labeled compounds can often be identified by using... 18 F, 33 S, 34 S, 35 S and / or 36 The preparation is carried out by replacing the non-isotope-labeled reagent with an S-labeled reagent, following the procedures disclosed in the schemes and / or examples described in this invention.

[1055] Containing the above 18 F, 33 S, 34 S, 35 S and 36 One or more of the S atoms in the compounds of the present invention, or their pharmaceutically acceptable salts or solvates, are within the scope of the present invention. Additionally, isotopes (e.g., 18 F, 33 S, 34 S, 35 S and / or 36 Substitution of S) can provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirement).

[1056] For the avoidance of doubt, it should be understood that in this specification, if a group is defined as “described in this invention”, then the group covers the first and broadest definition appearing in the specification, as well as each and all specific definitions of the group.

[1057] The various functional groups and substituents of a compound of formula (A) are typically chosen such that the molecular weight of the compound does not exceed 1000 Daltons. More typically, the molecular weight of the compound will be less than 1000, for example, less than 900, or less than 800, or less than 700, or less than 600 or less than 500.

[1058] As used herein, the term "isomerism" refers to compounds having the same molecular formula but differing in their atomic bonding sequence or their atomic spatial arrangement. Isomers with different atomic spatial arrangements are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are non-overlapping mirror images of each other are called "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual enantiomers with opposite chirality is called a "racemic mixture."

[1059] As used in this invention, the term "chiral center" refers to a carbon atom bonded to four different substituents.

[1060] As used in this invention, "chiral isomer" means a compound having at least one chiral center. Compounds having more than one chiral center may exist as individual diastereomers or as mixtures of diastereomers (referred to as "diastereomer mixtures"). When a chiral center is present, the stereoisomer can be characterized by the absolute configuration (R or S) of said chiral center. Absolute configuration refers to the spatial arrangement of substituents connected to the chiral center. The substituents considered connected to the chiral center are ordered according to the Cahn, Ingold, and Prelog Sequence Rule. (Cahn et al., Angew. Chem. Inter. Edit., 1966, 5, 385; errata 511; Cahn et al., Angew. Chem., 1966, 78, 413; Cahn and Ingold, Journal of the Chemical Society, 1951 (London), 612; Cahn et al., Experientia, 1956, 12, 81; Cahn, Journal of Chemistry Education, 1964, 41, 116).

[1061] As used in this invention, the term "geometric isomer" refers to the presence of diastereomers attributable to rotational hindering around a double bond or cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished by the prefixes cis and trans, or Z and E, which, according to the Cahn-Ingold-Prelog rule, indicate that the groups are on the same or opposite sides of the double bond in the molecule.

[1062] It should be understood that the compounds of the present invention can be described as different chiral isomers or geometric isomers. It should also be understood that when a compound has chiral or geometric isomers, all isomers are intended to be included within the scope of the present invention, and the naming of the compound does not exclude any isomer. It should be understood that not all isomers may have the same level of activity.

[1063] It should be understood that the structures and other compounds discussed in this invention include all their transisomers. It should also be understood that not all transisomers possess the same level of activity.

[1064] As used in this invention, the term "transisomer" refers to a class of stereoisomers with different atomic spatial arrangements. The presence of transisomers is attributed to rotational restriction caused by the impaired rotation of the large group around the central bond. Such transisomers are usually present as mixtures; however, due to recent advances in chromatographic techniques, mixtures of two transisomers can now be separated under selected conditions.

[1065] As used in this invention, the term "tautomer" is one of two or more structural isomers that exist in equilibrium and readily transform from one isomer to another. This transformation results in the migration of hydrogen atoms, accompanied by the transformation of adjacent conjoined double bonds. Tautomers exist as a mixture of tautomers in solution. In solutions where tautomerization is possible, tautomers will reach chemical equilibrium. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that can interconvert through tautomerization is called tautomerism. Among the many possible types of tautomerism, two types are commonly observed. In keto-enol tautomerism, electrons and hydrogen atoms undergo simultaneous displacement. Ring-chain tautomerism occurs due to the reaction of an aldehyde group (-CHO) in a sugar molecule with one of the hydroxyl groups (-OH) in the same molecule to impart a cyclic (ring-shaped) form, as exhibited by glucose.

[1066] It should be understood that the compounds of the present invention can be described as different tautomers. It should also be understood that when a compound has tautomer forms, all tautomer forms are intended to be included within the scope of the present invention, and the naming of the compound does not exclude any tautomer form. It should be understood that some tautomers may have a higher level of activity than other tautomers.

[1067] Compounds with the same molecular formula but different atomic bonding properties or sequences or atomic spatial arrangements are called "isomers". Isomers with different atomic spatial arrangements are called "stereoisomers". Stereoisomers that are not mirror images of each other are called "diastereomers", and stereoisomers that are non-overlapping mirror images of each other are called "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog or by rotating the molecular polarization plane, and are designated as dextrorotatory or levorotatory (i.e., (+) or (-)- isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture".

[1068] The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds may be produced as individual (R)- or (S)- stereoisomers or mixtures thereof. Unless otherwise specified, the description or naming of particular compounds in the specification and claims is intended to include both individual enantiomers and racemic mixtures or other mixtures thereof. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry," 4th edition, J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by analytical methods in racemic forms. Some compounds of the present invention may have geometric isomer centers (E-isomers and Z-isomers). It should be understood that the present invention covers all optical, diastereomers and geometric isomers, and mixtures thereof, having inflammasome inhibitory activity.

[1069] This invention also covers compounds of the invention as defined herein, said compounds comprising one or more isotopic substitutions.

[1070] It should be understood that compounds of any kind described in this invention include the compound itself as well as its salts and solvates (if applicable). For example, salts can be formed between an anion and a positively charged group (e.g., an amino group) on the substituted compound disclosed in this invention. Suitable anions include chloride, bromide, iodide, sulfate, hydrogen sulfate, aminosulfonate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, toluenesulfonate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).

[1071] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation and a negatively charged group (e.g., a carboxylate) on the substituted compounds disclosed herein. Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations, such as tetramethylammonium or diethylamine ions. The substituted compounds disclosed herein also include those salts containing a quaternary nitrogen atom.

[1072] It should be understood that the compounds of the present invention (e.g., salts of the compounds) may exist in hydrated or non-hydrated (anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.

[1073] As used herein, the term "solvent" refers to a solvation form containing stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in a crystalline solid state, thereby forming a solvate. If the solvent is water, the formed solvate is a hydrate; and if the solvent is an alcohol, the formed solvate is an alcohol. A hydrate is formed by combining one or more water molecules with a substance in which water retains its molecular state as H₂O.

[1074] As used herein, the term "analogue" refers to a compound that is structurally similar to another but has a slightly different composition (e.g., by substituting an atom with an atom of a different element, or by substituting a functional group with another functional group in the presence of a specific functional group). Thus, an analogue is a compound that is similar or equivalent to a reference compound in function and appearance, but not similar or equivalent in structure or origin.

[1075] As used in this invention, the term "derivative" refers to a compound having a common core structure and being substituted with various groups as described in this invention.

[1076] As used herein, the term "bioisostere" refers to a compound resulting from the exchange of one atom or group of atoms with another substantially similar atom or group of atoms. The aim of bioisostere substitution is to produce new compounds with similar biological properties to the parent compound. Bioisostere substitution can be based on physicochemical or topological principles. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazolium, sulfonates, and phosphonates. See, for example, Patani and LaVoie, *Chem. Rev.* 96, 3147-3176, 1996.

[1077] It should also be understood that certain compounds of any of the formulas disclosed in this invention may exist in both solvated and non-solvated forms (e.g., hydrated forms). Suitable pharmaceutically acceptable solvates are, for example, hydrates, such as hemihydrates, monohydrates, dihydrates, or trihydrates. It should be understood that this invention covers all such solvated forms having inflammasome-inhibiting activity.

[1078] It should also be understood that certain compounds of any of the formulas disclosed in this invention may exhibit polymorphism, and this invention covers all such forms or mixtures thereof having inflammasome inhibitory activity. It is generally known that crystalline materials can be analyzed using conventional techniques such as X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy, near-infrared (NIR) spectroscopy, and solution and / or solid-state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials can be determined by Karl Fischer analysis.

[1079] Compounds of any of the formulas disclosed in this invention may exist in a variety of different tautomeric forms, and references to compounds of formula (A) include all such forms. For the avoidance of doubt, where a compound may exist in one of several tautomeric forms and only one tautomeric form is specifically described or shown, all other tautomeric forms are still included in formula (A). Examples of tautomeric forms include ketone forms, enol forms, and enolate forms, for example in the following tautomeric pairs: ketone / enol (shown below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thionone / enthiol, and nitro / acid nitro.

[1080] Compounds containing any of the formulas disclosed in this invention, which contain amine functional groups, can also form N-oxides. References to compounds of formula (A) containing amine functional groups in this invention also include N-oxides. In the case of compounds containing several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of tertiary amines or nitrogen atoms in nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, *Advanced Organic Chemistry*, Jerry March, 4th ed., Wiley Interscience, p. More specifically, N-oxides can be prepared using the LWDeady procedure (*Synthetic Communications*, 1977, 7, 509-514), in which the amine compound reacts with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.

[1081] Compounds of any of the formulas disclosed in this invention can be administered as prodrugs, which are broken down in the human or animal body to release the compounds of this invention. Prodrugs can be used to modify the physical properties and / or pharmacokinetic properties of the compounds of this invention. Prodrugs can be formed when the compounds of this invention contain suitable groups or substituents to which a characteristic modifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the ester or amide group of any of the formulas disclosed in this invention.

[1082] Therefore, when obtainable by organic synthesis and when obtainable in humans or animals by cleaving its prodrug, the present invention includes compounds of any of the formulas disclosed herein as defined above. Thus, the present invention includes compounds of any of the formulas disclosed herein produced by organic synthesis, as well as such compounds produced in humans or animals by the metabolism of precursor compounds; that is, compounds of any of the formulas disclosed herein can be synthetically produced or metabolically produced compounds.

[1083] A suitable pharmaceutically acceptable prodrug of any of the formulas disclosed in this invention is a prodrug that is suitable for administration to humans or animals without undesirable pharmacological activity and without excessive toxicity, based on reasonable medical judgment. For example, various forms of prodrugs have been described in the following literature: a) *Methods in Enzymology*, Vol. 42, pp. 309-396, edited by K. Widder et al. (Academic Press, 1985); b) *Design of Prodrugs*, edited by H. Bundgaard (Elsevier, 1985); c) *A Textbook of Drug Design and Development*, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5, “Design and Application of Prodrugs”, H. Bundgaard, pp. 113-191 (1991); d) H. Bundgaard, *Advanced Drug Delivery*. e) H. Bundgaard et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, Pro-Drugs as Novel Delivery Systems, ACS Symposium Series, Vol. 14; and h) E. Roche (ed.), Bioreversible Carriers in Drug Design, Pergamon Press, 1987.

[1084] Suitable pharmaceutically acceptable prodrugs of compounds having a hydroxyl group, any of the formulas disclosed in this invention, are, for example, esters or ethers that are cleavable in vivo. In vivo cleavable esters or ethers of compounds containing a hydroxyl group, any of the formulas disclosed in this invention, are, for example, pharmaceutically acceptable esters or ethers that are cleaved in the human or animal body to produce a parent hydroxyl compound. Pharmaceutically acceptable ester-forming groups suitable for hydroxyl groups include inorganic esters, such as phosphate esters (including cyclic aminophosphates). Other pharmaceutically acceptable ester-forming groups suitable for hydroxyl groups include C1-C1 esters. 10 Alkyl groups, such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups; C1-C 10 Alkoxycarbonyl groups, such as ethoxycarbonyl, N,N-(C1-C6 alkyl)2-carbamoyl, 2-dialkylaminoacetyl, and 2-carboxyacetyl. Examples of cyclic substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazine-1-ylmethyl, and 4-(C1-C4 alkyl)piperazine-1-ylmethyl. Pharmaceutically acceptable ether-forming groups suitable for the hydroxyl group include α-acyloxyalkyl groups, such as acetoxymethyl and neopentyloxymethyl.

[1085] Suitable pharmaceutically acceptable prodrugs of compounds having a carboxyl group in any of the formulas disclosed in this invention are, for example, amides that are cleavable in vivo, such as amides formed with: amines, such as ammonia; C 1-4 Alkylamines, such as methylamine; (C1-C4 alkyl)2amines, such as dimethylamine; N-ethyl-N-methylamine or diethylamine; C1-C4 alkoxy-C2-C4 alkylamines, such as 2-methoxyethylamine; phenyl-C1-C4 alkylamines, such as benzylamine; and amino acids, such as glycine, or esters thereof.

[1086] Suitable pharmaceutically acceptable prodrugs of compounds having an amino group, belonging to any of the formulas disclosed in this invention, are, for example, amide derivatives that are cleavable in vivo. Suitable pharmaceutically acceptable amides derived from an amino group include, for example, those with C1-C2 groups. 10 Amides formed from alkyl acyl groups (such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups). Examples of cyclic substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazine-1-ylmethyl, and 4-(C1-C4 alkyl)piperazine-1-ylmethyl.

[1087] The in vivo effects of compounds of any of the formulas disclosed in this invention can be exerted in part through one or more metabolites formed in the human or animal body following administration of a compound of any of the formulas disclosed in this invention. As stated above, the in vivo effects of compounds of any of the formulas disclosed in this invention can also be exerted through the metabolism of a prodrug compound. Methods for synthesizing compounds

[1088] The compounds of this invention can be prepared by a variety of methods, including standard chemistry. Suitable synthetic routes are described in the following schemes.

[1089] Compounds of formula (A) can be prepared by methods known in the field of organic synthesis as partially described in the ...

Claims

1. A compound, characterized in that include: Formula (A): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; R M Selected from M is selected from 5-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; R 1 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 2 Together is the oxygen; or R 2 and R 3 together to form a bond; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; R 4 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 4 Together with the atoms to which it is attached and any intervening atoms, it forms a 3-10 membered cycloalkyl, a 6-10 membered aryl, a 3-14 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted by one or more R 16 replace; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Yes - (CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; R 9 , R 10 , R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl is optionally substituted by one or more R 16 replace; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; n is an integer selected from 0, 1 and 2; m is an integer selected from 0 and 1; The condition is that when R q When it is H, then R 1 and R 4 Together with the atoms to which it is attached and any intervening atoms, it forms a 3-10 membered cycloalkyl, a 6-10 membered aryl, a 3-14 membered heterocycle, or a 5-6 membered heteroaryl; in, Cycloalkyl is a monocyclic or polycyclic saturated carbocyclic ring containing 3 to 18 carbon atoms; Aryl is a cyclic aromatic hydrocarbon group having 1 to 3 aromatic rings; Heterocyclyl is a saturated or partially unsaturated 3-10 membered monocyclic, 7-12 membered bicyclic (fused, bridged or spiro) or 11-14 membered tricyclic ring system (fused, bridged or spiro) having one or more heteroatoms selected from O, N, S, P, Se or B; Heteroaryl is a monovalent monocyclic or polycyclic aromatic group having 5 to 24 ring atoms, which contains one or more ring heteroatoms selected from N, O, S, P or B, and the remaining ring atoms are C.

2. The compound according to claim 1, characterized in that The compound comprises formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; R 1 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 2 Together is the oxygen; or R 2 and R 3 together to form a double bond; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; R 4 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 4 Together with the atoms to which it is attached and any intervening atoms, it forms a 3-10 membered cycloalkyl, a 6-10 membered aryl, a 3-14 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted by one or more R 16 replace; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Yes - (CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; R 9 , R 10 , R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl is optionally substituted by one or more R 16 replace; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; n is an integer selected from 0, 1 and 2.

3. The compound according to claim 1, characterized in that The compound comprises formula (II): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; M is selected from 5-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; R 1 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 2 Together is the oxygen; or R 2 and R 3 together to form a double bond; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; R 4 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; or R 1 and R 4 Together with the atoms to which it is attached and any intervening atoms, it forms a 3-10 membered cycloalkyl, a 6-10 membered aryl, a 3-14 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted by one or more R 16 replace; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Yes - (CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; m is an integer selected from 0 and 1; n is an integer selected from 0, 1, and 2.

4. The compound according to claim 1, characterized in that The compound comprises formula (A'): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; R M Selected from M is selected from 5-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; C is a ring selected from the group consisting of 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; or R 2 and R 3 together to form a bond; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Yes - (CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; R 9 , R 10 , R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl is optionally substituted by one or more R 16 replace; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; n is an integer selected from 0, 1, 2; m is an integer selected from 0 and 1; x is an integer selected from 0, 1, 2, 3 and 4.

5. The compound according to claim 2, characterized in that The compound comprises formula (I'): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; C is a ring selected from the group consisting of 3-10 membered cycloalkyl, 6-10 membered aryl, 3-14 membered heterocycle, or 5-6 membered heteroaryl; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; or R 2 and R 3 together to form a double bond; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Selected from -(CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; R 9 , R 10 , R 11 Each is independently selected from C1-C6 alkyl, cycloalkyl, halogen, -CN; R 12 Selected from R 6 -S(O)2-、R 6 -C(O)-、R 6 -OC(O)-, heteroaryl, wherein the heteroaryl is optionally substituted by one or more R 16 replace; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; n is an integer selected from 0, 1, 2; x is an integer selected from 0, 1, 2, 3 and 4.

6. The compound according to claim 3, characterized in that The compound comprises formula (II'): or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or tautomer thereof, in: Each R N Independently selected from H, C1-C6 alkyl, cycloalkyl; Q is for CR 5 R Q or NR Q ; R q It is H; R Q YesR N ;or R q and R Q together to form a bond; M is selected from 5-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; C is a ring selected from cycloalkyl, aryl, heterocyclyl or heteroaryl; R 2 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; R 3 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted by one or more R 16 replace; or R 2 and R 3 together to form a bond; R 5 Selected from hydrogen, halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R 16 replace; Each R 6 independently selected from H, C1-C6 alkyl, cycloalkyl, -CH2-aryl, wherein the alkyl, cycloalkyl or aryl is optionally substituted by one or more R 16 replace; R 7 Selected from -(CH2) n Aryl, wherein the aryl group is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; R 8 is selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl; or R 7 and R 8 Together with the atoms to which it is attached and any intervening atoms, it forms a 13 substituted 5-7 membered monocyclic or bicyclic heterocyclic group; Each R 13 Independently selected from halogen, -OH, -CN, -C1-C6 alkyl, -C1-C6 haloalkyl; Two R's 13 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; R 14 and R 15 Each is independently selected from H, C1-C6 alkyl, cycloalkyl; or R 14 and R 15 Together with the atoms to which it is attached and any intermediate atoms, it forms a heterocyclic group optionally substituted with one or more halogen, -OH, -CN, C1-C6 alkyl; Each R 16 Independently selected from halogen, -OH, -CN, -NO2, -NR 14 R 15 , C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, -C(O)OR 14 、-C(O)R 14 、-C(O)N-NR 14 R 15 , cycloalkyl, -O-cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; or Two R's 16 Together with the atoms to which it is attached and any intervening atoms, it forms a 5-8 membered cycloalkyl, a 6 membered aryl, a 5-8 membered heterocycle, or a 5-6 membered heteroaryl, wherein the cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl; X is selected from hydrogen, halogen, OH, CN, NO2, CONH2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NHC1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein alkyl is optionally substituted by cycloalkyl, heterocyclyl, aryl and heteroaryl; m is an integer selected from 0 and 1; n is an integer selected from 0, 1, 2; x is an integer selected from 0, 1, 2, 3 and 4.

7. The compound according to claim 5, characterized in that The compounds include formula (II-II-VI): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

8. The compound according to claim 5, characterized in that The compounds include formula (I-II-II-AA): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

9. A compound, characterized in that Selected from: or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

10. A pharmaceutical composition, characterized in that Comprising the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or tautomer thereof, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition according to claim 10, characterized in that Further comprising an additional pharmaceutically active agent.

12. A method for inhibiting coronavirus replication, characterized in that: The method comprises administering to a subject a compound according to any one of claims 1 to 9 or a pharmaceutical composition according to any one of claims 10 or 11.

13. A method for treating a disease or condition associated with coronavirus infection, characterized in that: The method comprises administering to a subject a compound according to any one of claims 1 to 9 or a pharmaceutical composition according to any one of claims 10 or 11.

14. A method for treating coronavirus infection, characterized in that: The method comprises administering a compound according to any one of claims 1 to 9 or a pharmaceutical composition according to any one of claims 10 or 11 to a subject in need of treatment.

15. The method according to claim 14, characterized in that The coronavirus infection is COVID-19.

16. The method according to any one of claims 12 to 15, characterized in that The subject is a human.

Images